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Abstract:  Lifestyle  interventions  (i.e.,  diet  and/or  physical  activity)  are  effective  in 
delaying  or  preventing  the  onset  of  diabetes  and  cardiovascular  disease.  However, 
policymakers must know the cost-effectiveness of such interventions before implementing 
them  at  the  large-scale  population  level.  This  review  discusses  various  issues  (e.g., 
characteristics,  modeling,  and  long-term  effectiveness)  in  the  economic  evaluation  of 
lifestyle  interventions  for  the  primary  and  secondary  prevention  of  diabetes  and 
cardiovascular  disease.  The  diverse  nature  of  lifestyle  interventions,  i.e.,  type  of 
intervention, means of provision, target groups, setting, and methodology, are the main 
obstacles to comparing evaluation results. However, most lifestyle interventions are among 
the intervention options usually regarded as cost-effective. Diabetes prevention programs, 
such  as  interventions  starting  with  targeted  or  universal  screening,  childhood  
obesity  prevention,  and  community-based  interventions,  have  reported  favorable  
cost-effectiveness ratios. 
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1. Introduction 
 
Cardiovascular  disease  (CVD)  and  diabetes  are  the  leading  causes  of  death  worldwide.  An 
estimated 17.1 million people died from CVD in 2004, representing 29% of all global deaths. Diabetes 
causes approximately 5% of all deaths globally each year and its incidence is predicted to increase by 
over 50% in the next 10 years, according to the World Health Organization (WHO) [1]. People with 
diabetes develop CVD at an earlier age and are two to four times more likely to suffer strokes than 
healthy  subjects,  and  approximately  73%  of  adults  with  diabetes  are  considered  pre-hypertensive. 
These  diseases  also  impose  a  substantial  economic  burden  on  individuals,  families,  and  nations. 
Healthcare expenditures for diabetes are expected to account for 11.6% of total healthcare spending in 
the world in 2010 [2]. Besides excess healthcare expenditures, diabetes and CVD also impose costs in 
terms  of  lost  productivity  and  foregone  economic  growth  due  to  lost  work  days,  lower  work 
productivity, mortality, and permanent disability [3]. 
Lifestyle  interventions,  i.e.,  changed  dietary  habits,  increased  physical  activity,  maintaining  or 
reducing body weight, and smoking cessation, are effective in preventing CVD and diabetes. In recent 
decades,  numerous  studies  have  focused  on  preventing  type  2  diabetes  (T2DM)  via  lifestyle 
intervention. The Malmö  feasibility study was the first [4], followed by other controlled trials, such as 
the Da Qing study in China [5], the Diabetes Prevention Program (DPP) in the USA [6], and the 
Diabetes Prevention Study (DPS) in Finland [7]. These trials have had a significant impact on public 
health  policy,  providing  evidence  of  lifestyle  interventions  as  preventive  factors,  and  have  been 
followed  by  similar  studies  in  other  countries,  for  example,  India  [8],  Japan  [9],  and  The  
Netherlands  [10].  Reviews  of  lifestyle  interventions  have  also  indicated  that  diet  and/or  physical 
activity are effective in reducing CVD risk in primary care [11-14].  
As  evidence  supports  the  role  of  diet  and/or  physical  activity  in  preventing  T2DM  and  CVD, 
preventive strategies should aim to reduce population-wide risk. Such risk reduction interventions, 
even if modest, could cumulatively yield substantial benefits. Given the considerable cost of such 
interventions,  public  health  interventions  are  increasingly  subject  to  economic  evaluation  [15-17]. 
Economic evaluations comprise the comparative analysis of two or more healthcare interventions in 
terms of their costs and consequences. The results of such evaluations help public health policymakers 
make informed decisions, ensuring that limited resources are allocated as efficiently as possible to 
improve  overall  population  health  while  avoiding  allocating  resources  to  interventions  with 
comparatively  low  cost-effectiveness  [18,19].  The  number  of  economic  evaluations  of  diet  and/or 
physical activity interventions focusing on T2DM and CVD is also increasing. There is one review of 
the  cost-effectiveness  of  physical  activity  interventions,  but  not  specifically  regarding  CVD  or  
T2DM [20], one of dietary intervention to prevent CVD [21], and another of the cost-effectiveness of 
physical activity in treating disease [22]. There is also a review of economic evaluations of T2DM Int. J. Environ. Res. Public Health 2010, 7                 
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prevention [23], which updated three previous reviews. However, to our knowledge, no review has 
considered the health economic evidence regarding lifestyle interventions to prevent CVD and T2DM 
simultaneously,  although  these  diseases  share  lifestyle  risk  factors  (sometimes  referred  to  as  the 
metabolic syndrome [24,25]).  
Modeling has become a crucial component of economic evaluations. Computer simulation models 
are  usually  a  series  of  mathematical  equations  combined  in  a  structural  framework  to  allow  the 
projection  of  short-term  data  from  clinical  trials  to  long-term  health  outcomes  and  costs  [18]. 
Modeling is particularly relevant in the case of T2DM and CVD, since morbidity and mortality stem 
from chronic complications. Several models of diabetes and related complications and of CVDs have 
recently been developed [26,27]; for example, in the fourth Mount Hood Challenge, seven models of 
diabetes were analyzed [28]. There have been previous reviews of diabetes models [27,29], one of 
which concluded that models vary significantly in whether diabetes complications (micro vs. macro 
complications) are covered, and less in the detail of such coverage [29]. Several recent studies have 
incorporated  the  latest  epidemiological  data,  enabling  advanced  modeling  of  diabetes  and  
related complications. 
Models incorporate the short-term outcome of an intervention and project its lifetime effects. Since 
lifestyle interventions aim to change subject behavior, the beneficial habits are supposed to continue 
after the interventions have ended. For example, in a followup study of DPS, the intervention group 
maintained the beneficial lifestyle changes with the relative risk reduction of 36% after the three-year 
followup of a 4-year intervention period [30]. Unlike DPS, the 10-year followup of DPP demonstrated 
that diabetes incidence was the same in the lifestyle and control groups (5.9 vs. 5.6), but that the 
cumulative incidence was lower in the lifestyle group, leading the authors to conclude that diabetes 
can be prevented or delayed for at least for 10 years by means of lifestyle intervention [31]. The 20-
year followup study of Da Qing demonstrated that lifestyle intervention still had positive effects on the 
incidence of T2DM in the intervention group [32], but had no significant effect on CVD events, CVD 
mortality,  or  all-cause  mortality  relative  to  the  control  group.  The  DPS  followup  study  also 
demonstrated that the effect of lifestyle intervention on 10-year CVD mortality was same in both 
control  and  intervention  groups,  unlike  the  Malmö   preventive  trial  in  which,  after  12  years  of 
followup, total mortality was lower for lifestyle participants [33]. Although there are unresolved issues 
concerning  the  long-term  effectiveness  of  lifestyle  interventions,  economic  evaluation  of  lifestyle 
interventions  requires  empirical  evidence  or  logical  assumptions  to  model  probable  future  
health outcomes. 
This  review  critically  appraises  the  literature,  particularly  seeking  to  answer  the  following 
questions: 
1. How have economic evaluation of lifestyle interventions (i.e., diet and/or physical 
activity) been implemented in preventing T2DM and CVD? 
2. What models have been used in conducting these evaluations? 
3. What  assumptions  have  been  made  regarding  the  long-term  effectiveness  of 
interventions when modeling beyond the intervention period? Int. J. Environ. Res. Public Health 2010, 7                 
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2. Methods 
 
2.1. Search Process 
 
We  searched  databases  containing  only  economic  studies,  such  as  the  British  National  Health 
Service Economic Evaluation Database (NHS EED) (available at http://www.crd.york.ac.uk/crdweb/), 
and  cross-checked  against  the  CEA  registry  (available  at  https://research.tufts-nemc.org/cear/ 
search/search.aspx), as recommended by Pignone et al. [34] and done by others [35,36]. NHS EED 
contains  articles  from  four  major  databases,  i.e.,  Current  Contents–Clinical  Medicine,  MEDLINE, 
CINHAL,  and  EMBASE,  starting  from  1995.  This  database  also  includes  studies  from  PsychLit, 
Biomed Central, paper-based journals, and other gray literatures. Using the search terms *Lifestyle*, 
*Diet*,  and  *Physical  activity*,  115  lifestyle,  186  diet,  and  146  physical  activity  articles  were 
retrieved. All articles were exported to EndNote for review. 
 
2.2. Inclusion and Exclusion Criteria 
 
The  first  and  last  authors  independently  reviewed  the  article  abstracts.  The  article  search  was 
limited to the 1995–2008 period. Duplicate articles were removed from EndNote, since some articles 
contained  the  same  keywords.  At  this  point,  the  CEA  database  was  cross-checked  for  additional 
articles. The criteria for article selection were full economic evaluation, i.e., cost-consequence analysis 
(CCA),  cost-effectiveness  analysis  (CEA),  cost-utility  analysis  (CUA),  and  cost-benefit  analysis 
(CBA).  Studies  involving  partial  economic  evaluation,  cost  of  illness,  or  literature  review  were 
excluded. Only articles published in English were included. Studies unrelated to CVD or T2DM (e.g., 
studies of cancer or osteoporosis) were also excluded.  
Mainly primary prevention, i.e., participants were healthy at time of intervention, and secondary 
prevention, i.e., participants were at high risk of developing diseases such as obesity or had impaired 
glucose tolerance (IGT)/impaired fasting glycemia (IFG), were included. Studies were excluded if 
participants had CVD or T2DM before intervention initiation. Studies were excluded in which lifestyle 
interventions  (e.g.,  smoking  cessation  or  reduced  alcohol  consumption)  did  not  include  dietary 
modification and/or physical activity. Pharmacotherapy was included if any lifestyle intervention was 
combined with drug treatment, or if it was a comparator for the analysis. Studies were excluded in 
which  lifestyle  interventions  were  compared  with  treatments  such  as  gastric  bypass  surgery, 
therapeutic nutrition, and enteral nutrition. After fulfilling all criteria, 47 articles were selected for 
review;  four  articles  were  excluded  after  reading  the  full  text,  since  the  study  participants  had 
preexisting diabetes or CVD. Furthermore, the reference lists of articles were manually searched to 
find relevant articles, which added three articles. The review finally included a total of 46 articles. The 
search and article selection procedures are presented in Figure 1. 
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Figure  1.  Flow  chart  for  study  selection  for  the  review  starting  with  the  
NHS EED database. 
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3. Results 
 
The reviewed interventions vary from simple provision of information about behavioral changes to 
active participation and screening for diabetes or CVD, which might involve universal screening or 
targeted screening of high-risk groups. The comparator of the studies also varies, being placebo care, 
standard  care,  or  lifestyle  intervention  alone,  especially  when  pharmacological  interventions  are 
evaluated. The target groups range from school-aged children to subjects over 65 years old. The risk 
factors vary, the populations ranging from generally healthy to high-risk (i.e., overweight, obese, and 
IGT/IFG positive), sometimes being gender specific (i.e., five articles examined female participants 
and  one  examined  males).  The  intervention  settings  are  also  diverse:  some  articles  analyze  new 
hypertension guidelines or national policies for countering overweight, others evaluate community or 
primary  care  settings,  and  three  studies  are  school  based.  The  evaluation  countries  are  mainly 
developed ones, primarily the USA, followed by the UK, with only one study (the Indian Diabetes 
Prevention Programme—IDPP) from India. Only one study is a CBA; three are CCAs and the rest are 
either CEAs or CUAs. In the CUA, effectiveness is measured as quality-adjusted life years (QALYs), 
whereas in the CEAs the measure of effectiveness varies considerably, for example, being life years 
gained (LYG), incidence of T2DM prevented or delayed, percentage point decrease in 10-year CVD 
risk, or number needed to treat to prevent one case of diabetes. The effectiveness data are derived from 
single randomized controlled trials or from literature reviews of trials from the country of a particular 
intervention study, if available, and otherwise from other countries. Results are sometimes presented 
as the incremental cost-effectiveness ratio (ICER), i.e., the ratio of the differences in costs between 
two alternatives to the differences in effectiveness between the same two alternatives (Tables 1–5 
present only the results of lifestyle interventions). The discount rate ranges from 3% to 6%. Most 
studies use the same discount rate for costs and effects, although different rates are used, for example, 
in  all  studies  from  the  Netherlands,  where 4%  is  used  for costs  and  1.5%  for effects. Sensitivity 
analyses are univariate, multivariate, or probabilistic. Of the 46 studies, 31 include decision analytic 
models (DAMs), such as decision trees, Markov models, and an Archimedes model.  
Methodological variation affecting how results are derived makes intra- or inter-group comparison 
between the studies difficult. However, concentrating only on the monetary figures in the results and 
agreeing  on  what  is  considered  cost-effective  (50,000  US$/QALY,  20,000–30,000  £ /QALY  or  
50,000 AU$/QALY), most lifestyle interventions are deemed cost-effective. 
   
3.1. General Characteristics of the Studies 
 
The papers are divided into five groups: (1) DPP-like lifestyle interventions, (2) physical activity 
interventions,  (3)  dietary  interventions,  (4)  diet  +  physical  activity  interventions,  and  (5)  drug 
treatment combined with any of the preceding interventions (Sections 3.1.1.–3.1.5.; Tables 1–5).  
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Table 1. General characteristics of articles on DPP, DPS, and IDPP. 
First author, 
year 
Intervention  Comparator 
Age, risk 
factor 
Country, 
type of EE 
Intervention 
period 
Perspectiv
e 
Effectiveness 
measure 
Effectivenes
s source 
Results and 
conclusion 
Price 
year, 
discount 
rate 
Sensitivity 
analysis 
Model 
Ackermann ‘06 
 [40] 
DPP lifestyle 
intervention 
Standard 
care 
≥25 y, BMI 
≥ 24, IGT 
USA, CUA  3 years  Healthcare  QALY 
Single study 
(DPP) 
1,288 US$/QALY 
2000, 
3% 
Univariate  DAM 
Caro 
‘04 
[43] 
Acarbose, 
intensive 
lifestyle 
intervention, 
metformin 
No 
intervention 
40–70 y, 
BMI > 25, 
IGT 
Canada, 
CEA 
5 years  Healthcare 
Preventing 
diabetes, LYG 
DPP, DPS, 
and for 
acarbose 
STOP-
NIDDM trial 
ICER Lifestyle 
intervention 749 vs. 
no intervention, 
7,252 vs. metformin, 
9,988 vs. acarbose 
(CA$/LYG) 
2000, 
5% 
Univariate  DAM 
DPP RG ‘03 
[37] 
DPP lifestyle 
intervention 
Standard 
care 
≥25 y,  
BMI ≥ 24, 
IGT 
USA, CUA  3 years 
Healthcare 
and societal 
Per case of 
diabetes 
delayed/prevented
, QALY 
Single study 
(DPP) 
51,600 US$/QALY 
societal perspective 
2000, 
3% 
Univariate 
No 
model 
Eddy ‘05 
[44] 
DPP lifestyle 
intervention, 
no intervention 
initially then 
dietary advice, 
no intervention 
initially then 
DPP, 
metformin. 
No 
intervention 
Adult, BMI 
> 24, fasting 
plasma 
glucose 
5.27–6.93 
mmol/L 
USA, CUA  3 years 
Healthcare 
and societal 
QALY 
DPP and 
literature 
review 
143,000 US$/QALY 
healthcare and 
62,600 US$/QALY 
societal perspective 
for DPP lifestyle 
intervention 
2000, 
3% 
Univariate 
Archim
edes 
model Int. J. Environ. Res. Public Health 2010, 7                 
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Table 1. Cont. 
Galani 
‘07 
[47] 
Lifestyle 
intervention 
(DPS) 
Standard 
care 
≥25 y; 
overweight 
BMI  
25–29.9, 
borderline 
BMI 30, 
moderate 
obese BMI 
> 30 
Switzerland
, CEA, 
CUA 
3.2 years  Societal  LYG, QALY 
Literature 
review 
64 CHF/QALY for 
females and  
354 CHF/QALY for 
males in borderline 
group 
2006, 
3% 
Probabilistic  DAM 
Galani 
‘08 
 [46] 
Lifestyle 
intervention 
(DPS) 
Standard 
care 
≥25 y, 
overweight 
BMI  
25–29.9, 
borderline 
BMI 30, 
moderate 
obese BMI 
> 30 
Switzerland
, CUA 
3.2 years  Societal  QALY 
Literature 
review 
ICER 4,358 
CHF/QALY 
(females) and 2,189 
CHF/QALY 
(males), 30 years 
old and overweight 
2006, 
3% 
Probabilistic  DAM 
Herman ‘05 
[38] 
DPP lifestyle 
intervention 
Standard 
care 
≥25 y,  
BMI ≥ 24, 
IGT 
USA, CUA  3 years 
Healthcare 
and societal 
QALY 
Literature 
review 
1,100 US$/QALY 
healthcare and 8800 
US$/QALY societal 
perspective 
2000, 
3% 
Univariate, 
probabilistic 
DAM 
Hoerger 
‘07  
 [41] 
Targeted 
screening (IGT 
& IFG 
positive) and 
either IGT or 
IFG positive + 
lifestyle 
No screening 
45–74 y, 
BMI ≥ 25 
USA, CUA 
until 
participants 
get diabetes 
Healthcare  QALY 
Literature 
review 
8,181 US$/QALY 
for (IGT + IFG) and 
9,511 US$/QALY 
for (IGT/IFG) 
2001, 
3% 
Univariate  DAM Int. J. Environ. Res. Public Health 2010, 7                 
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Table 1. Cont. 
Icks ‗07 
 [42] 
Targeted 
screening + 
lifestyle, 
targeted 
screening + 
metformin 
No 
intervention 
60–74 y, 
BMI ≥ 24 
Germany, 
CEA 
3 years 
Healthcare 
and societal 
Incidence of 
T2DM avoided 
DPP and 
literature 
review 
4,664 Euro 
healthcare and 
27,015 Euro societal 
perspective per case 
T2DM avoided by 
lifestyle intervention 
2004, 
NP 
Univariate, 
probabilistic 
DAM 
Lindgren ‘07  
 [48] 
Lifestyle 
intervention 
(DPS) 
No 
intervention 
60 y,  
BMI > 25, 
fasting 
glucose > 
6.1 mmol/L 
Sweden 
CUA 
3 years  Societal  LYG 
Single study 
(DPS) 
ICER 127,065 
societal and 98,725 
healthcare 
perspective with 
declining effect and 
141,555 societal and 
11,642 healthcare 
with remaining 
effect (SEK/LYG) 
2000, 
3% 
Univariate  DAM 
Palmer ‘04  
 [39] 
Intensive 
lifestyle 
advice, 
standard 
lifestyle advice 
+ metformin 
Standard 
lifestyle 
advice 
≥25 y, mean 
body weight 
94.2, mean 
BMI 34 
Australia, 
UK, France, 
Germany, 
Switzerland
, CEA 
3 years  Healthcare 
LYG, years free of 
T2DM 
DPP and 
literature 
review 
Country specific; 
lifestyle and 
metformin were cost 
saving in all 
countries except UK 
2002, 5% 
(UK 6% 
cost, 1.5% 
effect) 
Univariate  DAM 
Ramachandran 
‘07 [45] 
Lifestyle 
intervention, 
metformin, 
lifestyle 
intervention + 
metformin 
Standard 
lifestyle 
advice 
35–55 y, 
reproducibl
e IGT 
India, CEA  3 years  Healthcare 
Preventing one 
case of diabetes 
Single study 
(IDPP) 
Lifestyle 
intervention  
1,052 US$, lifestyle 
+ metformin  
1,359 US$ per case 
of diabetes 
prevented 
2006, 
NP 
Univariate 
No 
model 
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Table 2. General characteristics of articles on physical activity (PA). 
First 
author, 
year 
Intervention  Comparator 
Age, 
risk 
factor 
Country, 
type of EE 
Intervention 
period 
Follow 
up 
Perspectiv
e 
Effectiveness 
measure 
Effectiveness 
source 
Results and 
conclusion 
Price year, 
discount 
rate 
Sensitivity 
analysis 
Model 
Dalziel 
‘06 
 [55] 
Prescription-
based PA 
counseling by 
GP 
Standard care 
40–79 y, 
not 
active 
New 
Zealand, 
CUA 
3 weeks to 2 
years 
-  Healthcare 
Number of 
participants 
became active, 
QALY 
Single study 
(RCT) 
ICER 2,053 
NZ$/QALY 
2001, 
5% 
Univariate, 
probabilistic 
DAM 
Munro 
‘04  
[56] 
Twice weekly 
physical 
exercise 
No intervention 
≥65 y, 
not 
active 
UK, 
CUA 
2 years  -  Healthcare  QALY  Single study 
ICER 17,174 
€/QALY 
2003/2004, 
NP 
 
Not clear 
No 
model 
Roux 
‘08 
 [54] 
Promotion of 
PA 
No intervention  25–64 y 
USA, 
CUA,CEA 
-  -  Societal  QALY 
From 7 trials 
and the 
literature 
ICER 14,286 to 
68,557 
US$/QALY 
2003, 
3% 
Univariate, 
probabilistic 
DAM 
Sevick 
‘00  
[87] 
Lifestyle PA 
(behavioral skill 
training to 
increase PA) 
Structured PA 
(prescription, 
supervised, 
centre based) 
35–60 y, 
>140% 
ideal 
weight 
USA, 
CCA 
6 months 
24 
months 
Healthcare 
Several 
consequences for 
PA level and 
cardio-respiratory 
fitness 
Single study 
Lifestyle 
intervention is 
cost-effective 
Not 
mentioned, 
5% 
Univariate 
No 
model 
Stevens 
‘98 
 [57] 
Prescription-
based PA 
No prescription 
45–74 y, 
Not 
active 
UK, 
CEA, CCA 
10 weeks 
8 
months 
Healthcare 
Moving a person 
from sedentary to 
physically active 
level 
Single study 
(RCT) 
2,500 £ /person 
moving from 
inactive 
Not 
mentioned, 
NP 
Univariate 
No 
Model 
Sims 
‘04 
 [88] 
Exercise 
counseling by 
GP 
Standard care 
20–75 y, 
not 
active 
Australia, 
CEA 
1 year  -  Healthcare 
DALY saved and 
percentage of 
patients become 
active 
Single study 
(RCT) 
138 
AU$/patients 
become active, 
3,647 
AU$/DALY 
1996, 
NP 
Univariate 
No 
model 
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Table 3. General characteristics of articles on dietary interventions. 
First author, 
year 
Intervention  Comparator 
Age, 
risk 
factor 
Country, 
type of 
EE 
Intervention 
period 
Perspective 
Effectiveness 
measure 
Effectivenes
s source 
Results and conclusion 
Price year, 
discount 
rate 
Sensitivity 
analysis 
Model 
Cox ‘03  
 [62] 
Face-to-face 
food behavior 
changing session 
Self-
administered 
video lesson 
15–52 
y, 
low 
income 
USA, 
CEA 
3 months 
Not 
mentioned 
A behavior 
checklist and 
intake of various 
nutrients 
Single study 
Video lesson was less costly 
4,820 (US$) than face-to-face 
lesson 13,463 (US$) 
Not 
mentioned 
Not clear 
No 
model 
Dalziel ‘07  
 [60] 
10 nutritional 
interventions 
Details of all 
comparators 
not provided 
- 
Australia, 
CEA, 
CUA 
12 months  Societal  QALY 
Literature 
review 
Mediterranean diet 1,020, 
intensive lifestyle intervention 
1,880, media campaign for 2 
fruits & 5 vegetables 46, media 
campaign for fighting fit, 
fighting fat 5,600 (AU$/QALY) 
2003, 
5% 
Univariate  DAM 
Joffers 
‘07  
[89] 
Reduction in 
dietary sodium 
consumption 
Standard care  - 
Canada, 
CEA 
1 year 
Not 
mentioned 
Decrease in 
hypertension 
prevalence, cost 
savings 
Literature 
review 
430 million CA$/ year  Not clear, NP  NP 
No 
model 
Panagiotakos  
‘07  
 [90] 
People having 
diet close to 
Mediterranean 
diet 
People 
having 
traditional 
diet 
Adults 
Greece, 
CEA 
- 
Not 
mentioned 
Time free of the 
development of 
CHD and life 
years lost 
Single study 
(RCT) 
ICER 50,989 Euro for additive 
healthcare cost due to non-
Mediterranean diet for each year 
lost 
Not 
mentioned 
NP 
No 
model 
Tice ‘01 
 [61] 
Grain 
fortification with 
folic acid and 
also vitamin 
supplementation 
No 
fortification 
35–65 
y 
USA, 
CUA 
-  Healthcare 
Reduction in 
CHD events, 
medical cost 
savings and 
QALY saved 
Literature 
review 
For men ≥ 45 years, 300,000 
QALYs and women >55 years, 
140,000 QALYs will be saved in 
10 years 
1997, 
3% 
Multivariat
e 
DAM 
 
 
 Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3161 
Table 4. General characteristics of articles on diet + physical activity. 
First author, 
year 
Intervention  Comparator 
Age, risk 
factor 
Country, 
Type of EE 
Intervention 
period 
Perspective 
Effectiveness 
measure 
Effectiveness 
source 
Results and conclusion 
Price year, 
discount 
rate 
Sensitivity 
analysis 
Model 
Bemelmans 
‘08 
 [63] 
Lifestyle 
intervention, 
community-based 
approach, 
combined 
intervention 
No 
intervention 
20–80 y, 
overweight 
for lifestyle 
Netherlands, 
CEA, CUA 
-  Healthcare 
LYG and 
QALY 
Two Dutch 
studies, QALY 
from literature 
Lifestyle 7,400, 
Community-based 
approach 5,000, 
Combined program 
5,700 (€/QALY) 
2004, 
4% to cost 
and 1.5% to 
effect 
Univariate  DAM 
Booth 
‘07 
 [64] 
New 
antihypertensive, 
current care 
guidelines 
including lifestyle 
counseling 
Previous 
guidelines 
40–74 y 
Finland, 
CEA, CUA 
-  Healthcare  LYG 
National Health 
Examination 
Survey 
New guidelines saved 
498 million Euro and 
49,000 LYG 
2001, 
5% 
Univariate  DAM 
Brown 
‘07 
 [66] 
Dietary habits 
and physical 
activity changes 
in school 
curriculum 
No 
intervention 
8–11 y, 
BMI ≥ 85th 
percentile 
USA, 
CUA, CBA 
3 years  Societal 
QALY, net 
benefit 
Single study 
900 US$/QALY, Net 
benefit US$ 68,125  
2004, 
3% 
Probabilistic 
No 
model 
Colagiuri ‘08 
 [65] 
Screening and 
preventing 
diabetes by 
means of lifestyle 
activities 
No 
intervention 
55–74 y and 
high risk 45–
54 y, obesity, 
hypertension, 
family history 
of diabetes 
Australia, 
CUA 
-  Not clear  DALY 
Epidemiologica
l data from 
Australia, DPP, 
DPS, UKPDS 
50,000 AU$/DALY 
2000, 
3% 
Univariate  DAM Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3162 
Table 4. Cont. 
Dzator 
‘04 
 [74] 
Information 
given by mail, 
mail + active 
participation 
No 
intervention 
Cohabiting 
couples 
Australia, 
CEA, 
CCA 
4 months  - 
Changes in 
16 variables, 
e.g., 
consumption 
of fat, fiber, 
fruit, and 
vegetables; 
BMI, PA, 
physical 
fitness, LDL, 
BP 
Single study 
(RCT) 
445.30 AU$/participant 
per unit change of 
outcome variable 
Not 
mentioned 
Univariate 
No 
model 
Finkelstein ‘02 
 [72] 
CVD screening 
+ enhanced 
lifestyle 
intervention 
CVD 
screening + 
minimum 
lifestyle 
intervention 
>50 y, low 
income 
USA, 
CEA 
1 year  Healthcare 
Percentage 
point 
decrease in 
10-year 
probability of 
CHD 
Single study 
637 US$/ percentage 
point reduction in CHD 
risk via intensive 
lifestyle 
Not 
mentioned
, 3%, 
NP 
No 
model 
Finkelstein ‘06 
 [71] 
Screening, 
intervention 
including 
nutrition, 
physical 
activity, 
smoking 
cessation 
No 
intervention 
40 -64 y, low 
income, 
uninsured 
USA, 
CEA 
1 year  Healthcare 
Percentage 
point 
decrease in 
10-year 
probability of 
CHD and 
LYG 
Single study 
470 US$/ percentage 
point reduction in CHD 
risk, 4400 US$/LYG 
Not 
mentioned
, 3% 
Univariate 
No 
model Int. J. Environ. Res. Public Health 2010, 7                 
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Table 4. Cont. 
Goldfield ‘01 
 [67] 
Family-based 
behavioral 
treatment in 
group + 
individual basis 
Group 
treatment 
only 
8–12 y, 
20–100% 
overweight 
USA, 
CEA 
12 months  Healthcare 
Percentage 
overweight 
change for 
children and 
parents, 
reduction in 
Z-BMI 
Single study 
(RCT) 
Group treatment is 
more cost- effective 
Not 
mentioned 
Not clear 
No 
model 
Jacobs ‘07 
 [75] 
Community 
intervention for 
total population, 
healthcare 
intervention for 
people at risk 
No 
intervention 
20–80 y,  
30–70 y, 
obese for 
intensive 
lifestyle 
Netherlands
, 
CUA 
5 years for 
community, 
3 years for 
healthcare 
Healthcare 
QALY and 
number of 
participants 
need to treat 
to prevent 
one case of 
diabetes or 
CVD in 20 
years 
Literature 
review 
3,100–3,900 €/QALY 
for community 
intervention and 
3,900–5,500 €/QALY 
for healthcare 
intervention 
2005, 
4% to cost 
and 1.5% 
to effect 
Univariate  DAM 
Lindholm ‘96 
 [69] 
Screening + 
advice on 
lifestyle changes 
No 
intervention 
30–60 y, 
living in 
higher CVD 
mortality 
community 
Sweden, 
CEA 
6 years  Societal 
Change in 
serum 
cholesterol 
level, blood 
pressure, 
LYG 
Single study  1,100 to 4,050 £ /LYG 
1992, 
5% 
Univariate 
No 
model Int. J. Environ. Res. Public Health 2010, 7                 
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Table 4. Cont. 
Lindgren ‘03 
 [73] 
Diet, exercise, 
diet + exercise 
No 
intervention 
60 y, No 
CHD 
Sweden, 
CEA 
6 months 
Healthcare 
and societal 
LYG  Single study 
ICER 127,065 from 
societal and 98,725 
from healthcare with 
declining effect and 
141,555 from societal 
and 11,642 from 
healthcare with 
remaining effect 
(SEK/LYG) for diet 
2000, 
3% 
Univariate  DAM 
Mcconnon ‘07 
 [91] 
Use of website 
for changes in 
diet and physical 
activity 
Routine 
information 
in primary 
care 
>40 y, BMI 
> 31 
UK, 
CUA 
12 month  Not clear 
Changes in 
weight and 
BMI, QALY 
Single study 
(RCT) 
ICER 39,248 £ /QALY 
Not 
mentioned 
Probabilisti
c 
No 
model 
Salkeld ‘97  
[70] 
A video-based 
lifestyle change 
program, a video 
+ self-help 
program 
Standard 
care 
18–69 y, one 
or more 
CVD risk 
factor 
Australia 
CEA, CUA 
12 months  Societal  LYG, QALY 
One 
Australian trial 
and literature 
review 
ICER 152,128 
AU$/QALY for males 
in video + self help 
1994, 
5% 
Univariate  DAM 
Wang ‘03 
 [68] 
Dietary habits 
and physical 
activity changes 
in school 
curriculum 
No 
intervention 
14 y,  
BMI ≥ 85th 
percentile 
USA, CUA  2 years  Societal 
QALY, 
adulthood 
overweight 
prevented 
Single study 
(RCT) and 
others 
4,305 US$/QALY 
1996, 
3% 
Univariate 
multivariate 
DAM 
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Table 5. General characteristics of articles on combined drug and lifestyle intervention. 
First 
author, year 
Intervention  Comparator 
Age, risk 
factor 
Country,  
type of EE 
Intervention 
period 
Followup  Modeling 
Perspectiv
e 
Effectivenes
s measure 
Effectiven
ess source 
Results 
and 
conclusion 
Price year, 
discount 
rate 
Sensitivity 
analysis 
Model 
Ara ‘07 
 [76] 
Sibutramine 
+ diet and 
lifestyle 
Diet and 
lifestyle 
20–75+ 
y, BMI ≥ 
30 
Finland,Ge
rmany, 
UK, 
Switzerlan
d, CUA 
1 year  5 years  5 years  Healthcare  QALY 
Literature 
review 
2,149 for 
Finland, 
13,707 for 
Germany,1
0,734 for 
Switzerlan
d, 11,811 
for UK 
(€/QALY) 
2004, 
5%, UK 
(3.5%) 
Univariate  DAM 
Brennan ‘06  
[77] 
Sibutramine 
+ diet and 
lifestyle 
advice 
Diet and 
lifestyle 
>40 y, 
overweig
ht 
Germany, 
CUA 
1 year  5 years  5 years  Healthcare  QALY 
Literature 
review 
13,706 
€/QALY 
2003, 
5% 
Univariate  DAM 
Gillies ‘08 
 [84] 
Screening for 
T2DM, 
screening + 
lifestyle 
intervention, 
screening + 
drug 
No screening 
25/45–75 
y, BMI > 
25, other 
diabetic 
risk 
UK, CUA  -  -  50 years  Healthcare  QALY 
Literature 
review 
14,150 for 
screening, 
6,242 for 
screening + 
lifestyle, 
7,023 for 
screening + 
drug 
(£ /QALY) 
2006, 
3.50% 
Univariate, 
probabilisti
c 
DAM Int. J. Environ. Res. Public Health 2010, 7                 
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Table 5. Cont. 
Hampp ‘08 
 [81] 
Lifestyle 
intervention, 
lifestyle 
intervention + 
rimonabant 
No treatment 
≥18 y, 
BMI > 27 
or 30 
USA, CEA, 
CUA 
1–2 years  -  5 years  Healthcare  QALY 
Three 
published 
clinical 
trials 
52,936 
US$/QALY 
for 2 years 
rimonabant 
+ lifestyle 
2006, 
3% 
Univariate, 
probabilistic 
DAM 
Iannazzo ‘08  
 [79] 
Orlistat + 
lifestyle 
intervention 
Lifestyle 
intervention 
≥35 y, 
BMI > 30 
Italy, 
CUA 
4 years  6 years  10 years  Societal  QALY 
Single study 
(RCT) 
ICER 
75,300 
€/QALY 
Not 
mentioned, 
4% 
Probabilistic  DAM 
Prosser ‘00  
 [83] 
Low-
cholesterol 
diet, statins 
No 
intervention 
35–84 y, 
LDL ≥ 
160 mg/dl 
USA, 
CUA 
-  -  30 years  Societal  QALY 
Literature 
review 
ICER for 
diet ranged 
from 1,900 
US$ to 
500,000 
US$/QALY 
and statins 
from 54,000 
US$ to 
1,400,000 
US$ per 
QALY 
1997, 
3% 
Univariate  DAM 
Roux 
 ‘06 
 [82] 
Diet, diet + 
pharmacothera
py, diet + 
exercise, diet 
+ exercise + 
behavior 
modification 
Standard care 
35 y, BMI 
≥ 25 
USA, 
CEA, 
CUA 
6 months  6 months  Lifetime  Healthcare  QALY 
Literature 
review 
12,600 
US$/QALY 
for diet + 
exercise + 
behavior 
modification 
2001, 
3% 
Univariate  DAM Int. J. Environ. Res. Public Health 2010, 7                 
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Table 5. Cont. 
van Baal 
‘08 
 [80] 
Low-calorie 
diet, orlistat 
+ low-calorie 
diet 
No treatment 
20–70 y, 
BMI ≥ 30 
Netherland
s, 
CUA 
1 year  - 
up to 80 
years 
Healthcare  QALY 
Literature 
review 
ICER 
17,900 
€/QALY 
for  
low-calorie 
diet and 
58,800 
€/QALY 
for  
orlistat + 
low-calorie 
diet 
2005, 
1.5% to 
effect & 
4.0% to 
cost 
Univariate, 
probabilisti
c 
DAM 
Warren ‘04 
 [78] 
Sibutramine 
+ diet and 
lifestyle 
Diet and 
lifestyle 
18–65 y, 
BMI  
27–40 
UK and 
USA, 
CUA 
1 year  5 years  5 years  Healthcare  QALY 
Literature 
review 
ICER for 
sibutramine 
4,780 
£ /QALY 
2000, 
6% in UK 
and 3% in 
USA 
Univariate  DAM 
Abbreviations: BMI, body mass index; BP, blood pressure; CBA, cost–benefit analysis; CCA, cost-consequence analysis; CEA, cost-effectiveness analysis; CHD, coronary heart disease; 
CHF, Swiss franc; CUA, cost–utility analysis; CVD, cardiovascular disease; DALY, disability-adjusted life years; DAM, decision analytic model; DPP, Diabetes Prevention Program; DPS, 
Diabetes Prevention Study; EE, Economic evaluation; GP, general practitioner; ICER, incremental cost-effectiveness ratio; IDPP, Indian diabetes prevention program; IFG, impaired fasting 
glucose; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; LYG, life years gained; NP, not performed; PA, Physical activity; QALY, quality-adjusted life years; RCT, 
Randomized controlled trial; SEK, Swedish krona; T2DM; Type 2 diabetes; y, years. Int. J. Environ. Res. Public Health 2010, 7                 
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3.1.1. DPP-Like Lifestyle Interventions 
 
Economic evaluations of DPP-like lifestyle interventions have used different methodologies and 
produced  inconsistent  results.  The  first  economic  evaluation  of  DPP,  which  compared  lifestyle 
interventions  and  pharmacotherapy  (metformin)  with  placebo  care,  was  performed  by  the  DPP 
Research Group in 2003 [37]; it covered only the three-year intervention period without any DAM and 
from  a  societal  perspective.  As  DPP  intervention  costs  were  very  high,  it  was  proposed  that  the 
intervention be offered on a group basis (10 people per group) instead of face to face; it was assumed 
that the effectiveness would be similar, so that the costs of lifestyle intervention would be reduced. As 
a three-year time horizon overestimates the treatment costs and underestimates the benefits of lifestyle 
intervention and metformin, the same research group later extrapolated the trial data into lifetime costs 
and benefits using a Markov model [38]. The progression of IGT to clinical onset of diabetes and from 
diabetes-related complications to death was assessed. 
A  later  study  [39]  used  the  DPP  data  for  five  countries,  i.e.,  Australia,  France,  Germany, 
Switzerland, and the UK, applying a simple three-state Markov model (i.e., alive with IGT, alive with 
T2DM, and deceased) over a lifetime horizon. Another study analyzed the DPP results from a different 
perspective [40], i.e., whether investment in a DPP intervention program by a health insurer would cut 
costs. The model was same as that of the DPP Research Group but used for two time periods. The 
conclusion was that, if the insurer and Medicare shared the DPP intervention costs (24% borne by the 
insurer), the insurer would recover the investment via avoided future medical care costs. 
Two studies examined [41,42] screening for diabetes among overweight and obese people followed 
by DPP intervention, while  Icks  et al. [42] studied the cost-effectiveness of DPP in  a  real-world 
setting, i.e., when acceptance of and adherence to the intervention is low and the dropout rate is high. 
In addition to metformin, another drug, acarbose, was examined in Caro et al. [43] using a four-state 
Markov model of a Canadian population over ten years; this study estimated that lifestyle modification 
would prevent 117 cases of diabetes, while metformin and acarbose would prevent 52 and 74 new 
cases  of  diabetes,  respectively.  The  lifetime  cost  and  effectiveness  of  DPP  was  estimated  by  
Eddy et al. [44] using an Archimedes model, which contains infinite health states. This is the only 
study  estimating  that  DPP-like  lifestyle  intervention  has  a  mere  0.1%  chance  of  costing  under  
50,000 US$/QALY. 
DPP or DPP-like interventions have been studied in other countries as well. IDPP was performed 
by Ramachandran et al. [45]; although the analysis examined only the trial period (three years), the  
cost-effectiveness ratio was much lower than for DPP. Galani et al. reported two studies [46,47] on 
lifestyle interventions for overweight and obese Swiss population groups, with assumed effectiveness 
taken  from  DPS.  A  seven-state  Markov  model  over  a  lifetime  horizon  estimated  that  lifestyle 
intervention  could  be  cost-effective  depending  on  sex,  age  group,  and  threshold  values.  DPS 
effectiveness was applied to a Swedish population [48] using a Markov model, which included the cost 
of added life years. 
Methodological  disagreement  is  the  main  issue  in  DPP-like  studies.  The  results  of  DPP 
interventions  are  reported  as  8,800  US$/QALY  or  62,600  US$/QALY  depending  on  whether  a  
Markov [38] or Archimedes model [44] is applied. If 50,000 US$/QALY is considered a cutoff value 
for  cost-effectiveness,  the  same  trial  is  cost-effective  with  one  method  but  not  the  other.  The Int. J. Environ. Res. Public Health 2010, 7                 
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disagreement stems from different model assumptions on the rates of progression to diabetes and 
complications  [49,50].  Both  authors  provide  arguments  and  counterarguments  defending  their 
assumptions [51,52].  
Despite the disagreement, it was predicted that DPP-like lifestyle intervention would delay the 
onset of diabetes and lead to fewer complications, longer lives, and improved quality of life [50]. All 
the DPP/DPS/IDPP-like lifestyle interventions were cost-effective, except that reported by Eddy et al. 
[44], even if the intervention started with costly screening [41,42]. IDPP was much more cost-effective 
than similar programs in high-income countries, because the intervention cost was much lower even 
though staff went to participant homes to provide the intervention [45]. The cost-effectiveness ratio 
was in the cost-effective range when DPS was applied to a Swedish population [48], even though 
unrelated costs for added years of life were included, which is debatable [53]. 
 
3.1.2. Physical Activity Interventions  
 
Several  methods  have  been  used  to  determine the physical  activity  level of participants in  the 
economic evaluation of physical activity studies. One study used metabolic equivalent (MET) minutes 
per week to classify participants as inactive, irregularly active, meets guidelines, and highly active 
[54].  Some  studies  used  duration  and  intensity  of  physical  activity,  i.e.,  ≥2.5  hours  of  moderate 
intensity or vigorous exercise per week as marking a physically active person [55], while other studies 
used the self-administered physical activity questionnaire (PAQ) [56,57]. There were only two Markov  
models [54,55] of physical activity: the CDC MOVE Markov model was based on five diseases (i.e., 
coronary  heart  disease,  ischemic  stroke,  T2DM,  breast  cancer,  and  colon  cancer),  which  led  to 
underestimated cost-effectiveness, as physical activity also affects other diseases such as depression or 
anxiety [58].  
Indirectly measuring the level of physical activity (e.g., via PAQs) raises validity concerns [59]. 
The selection of participants for physical activity interventions is also a major concern, i.e., whether 
the control group also participates in the program or only includes motivated people; for example, one 
study [56] excluded highly active participants. Participation rate and adherence to physical activity are 
other important issues meriting attention when modeling the long-term benefits of physical activity. 
Surprisingly, the ICER of physical activity interventions is much lower in Australia [55] and New 
Zealand  than in  the USA [54] or  UK [56].  This  could be because  Roux et al. [54] analyzed the 
physical activity promotional intervention using a model containing considerably more health states 
and because the participants were older in the Munro et al. [56] study; however, all ICERs are in the  
cost-effective range. 
 
3.1.3. Dietary Interventions 
 
An economic evaluation of ten different nutritional interventions for the Australian population was 
performed by Dalziel and Segal [60]. Four Markov models were developed to analyze nutritional 
interventions. Reduction of dietary sodium intake to reduce hypertension, eating five servings of fruit 
and vegetables per day, and adhering to a ―Mediterranean-style‖ diet seemed to be cost-effective. The 
effect  of  the  Mediterranean  diet  was  estimated  to  reduce  the  10-year  CVD  risk  based  on  the Int. J. Environ. Res. Public Health 2010, 7                 
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Framingham risk equation. The cost-effectiveness of grains fortified with folic acid as well as vitamin 
supplementation with folic acid and cyanocobalamin (vitamin B12) to prevent coronary heart disease 
(CHD)  was  analyzed  in  one  study  [61]  of  the  entire  US  population  via  the  CHD  Policy  Model. 
Nutritional education was compared in Cox et al. [62], one group receiving traditional face-to-face 
advice, while another received self-administered video lessons. The effectiveness of the intervention 
was analyzed using a behavior questionnaire on changes in 10 dietary factors. 
There are few economic evaluations of dietary interventions and the quality of studies is often 
limited,  since  some  important  economic  evaluation  parameters  (i.e.,  age,  risk  factors,  sensitivity 
analysis,  and  price  year)  are  not  clearly  specified.  The  use  of  self-administered  questionnaires  to 
measure food intake raises validity issues. 
Dietary interventions are very diverse, and probably not very comparable. Moreover, varying study 
quality makes it difficult to compare the results of the dietary interventions, but fruit and vegetable 
intake has the lowest cost-effectiveness ratio (46 AU$/QALY) [60] and similar results are obtained 
from universal fortification of grains with folic acid. 
 
3.1.4. Diet + Physical Activity Interventions 
 
Three articles presented economic evaluations of a national policy or action plan [63-65]. The new 
Finnish  hypertension  care  guidelines  were  compared  with  previous  ones  [64],  which  did  not 
incorporate lifestyle intervention; the new guidelines were estimated to save an additional 49,000 life 
years.  The  Dutch  national  action  plan  for  counteracting  obesity  included  a  community-based 
intervention in which 90% of the population was screened and received lifestyle advice; an intensive 
lifestyle program was applied to 10% of the overweight adults in a healthcare setting. The combined 
program was evaluated using the RIVM chronic disease model, finding that it would save 110,000 life 
years  over  20  years  [63].  Using  a  diabetes  model  [65],  it  was  estimated  that  diabetes  care  and 
prevention  strategies  applied  to  the  entire  Australian  population  aged  45–74  years  would  prevent 
53,000 new cases of diabetes over 10 years. 
Three  articles  studied  childhood  obesity  prevention  programs  [66-68].  The  ―traffic  light  diet,‖ 
physical activity reinforcement, self monitoring, and stimulus control were used as interventions in 
one study; their effectiveness was measured as a reduction in standardized body mass index (Z-BMI) 
and proportion of overweight children [67]. Another study [68] examined Planet Health, a school-
based obesity prevention program focused on reducing television viewing, reducing consumption of 
high-fat foods, increasing fruit  and  vegetable consumption, and increasing moderate and vigorous 
physical activity. The randomized controlled trial included male and female subjects, but there were 
significant reductions in obesity only among female students after two school years. This intervention 
effect was then extrapolated up to age 64 years using a decision model measuring health benefits as 
QALYs.  The  same  method  was  used  in  another  study  [66]  of  a  different  school-based  obesity 
prevention program (CATCH) including male and female participants from grades three (age 8) to five 
(age 11). CATCH appears to be more cost-effective than the Planet Health program.  
Two  studies  have  focused  solely  on  reduction  of  CVD  incidence  using  the  Framingham  risk 
equation [69,70]. One study compared lifestyle interventions, including video and video + self-help 
guidelines,  with  routine  care  for  Australian  participants  at  risk  of  CVD  [70].  In  another  study, Int. J. Environ. Res. Public Health 2010, 7                 
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community-based education to change dietary habits to reduce total cholesterol level was estimated to 
prevent approximately 4.5 cases of CVD every year, with the highest benefit in the 55–64-year age 
group, in which it would prevent 8–9 cases [69] in a population of 5,500. The WISEWOMEN project, 
which aimed to reduce CVD risk in older uninsured and undernourished women by means of either 
CVD  screening  +  enhanced  lifestyle  intervention  or  CVD  screening  +  minimal  intervention,  was 
evaluated  in  two  studies  [71,72]. The earlier study [72] measured effectiveness as  the percentage 
reduction of the 10-year probability of having CVD, while the later study [71] measured it as LYG as 
well, resulting in a cost per LYG of US$ 4400. The effect of a single randomized controlled trial 
intervention of diet, exercise, and diet + exercise extrapolated on a cohort of 60-year-old healthy 
subjects without CVD was evaluated in one study [73]. The Markov model included 10 health states 
but  not  diabetes.  The  cost-effectiveness  of  interactive  group  sessions  advising  on  nutrition  and 
physical activity for cohabiting Australian couples was studied [74] on an intention-to-treat basis with 
outcomes measured on 14 variables (e.g., energy intake, fat intake, fiber intake, sodium, fruit and 
vegetable intakes, BMI, physical activity level, cholesterol profiles, and blood pressure). Two types of 
lifestyle intervention were evaluated by Jacobs et al. [75]—a community-based intervention for the 
general population covering many people at a relatively low cost, and a healthcare-based intervention 
for high-risk people covering fewer patients at a higher cost—using the RIVM chronic disease model. 
Many studies lack detailed information about certain important economic evaluation parameters 
and  on  how  data  have  been  derived, for example, via meta  analysis, systematic review, selective 
studies, or expert opinion. These parameters include cost (e.g., unit cost, total cost, intervention cost, 
disease cost, and productivity cost) [65,72,74], utility [63], and disability weight [65]. In childhood 
obesity  studies  [66,68],  the  explicit  assumption  requires  evidence,  which  is  missing,  from 
epidemiological studies linking childhood overweight to adult overweight and to weight regain after 
two-year interventions. The same issue applies in CVD cases: a time lag after termination of lifestyle 
intervention in improvements of CVD risk factors. Lindholm et al. [69] considered a five-year lag, 
whereas  
Dzator et al. [74] considered no time lag. The transferability of one country‘s clinical trial data to 
another [65] also requires adjustment. For community-based interventions [63,69,75], special attention 
is required to consider the spillover effect of lifestyle interventions and the efficacy of interventions in 
various socioeconomic groups, i.e., the equity concern is missing from the studies. However, the main 
question  concerns  the  applicability  of  intervention  effectiveness  data  from  clinical  settings  to  
real-world settings, particularly when national action plans or policies are being evaluated [63-65]. 
Interventions starting from childhood have a low cost-effectiveness ratio (900 US$/QALY) [66]. 
The  community-based  approach  is  also  attractive,  as  seen  in  the  Dutch  [63,75]  and  Swedish  
studies [69]. The advantage of community-based lifestyle prevention programs is that the health gains 
achieved through population-based approaches often exceed those achievable by targeting specific 
groups in clinical or subclinical settings.  
 
3.1.5. Combined Drug and Lifestyle Interventions 
 
Three articles [76-78] concerning the drug sibutramine were studied by the same research group 
using the same model but in different country settings, i.e., Finland, Germany, the USA, the UK, and Int. J. Environ. Res. Public Health 2010, 7                 
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Switzerland. Lifestyle intervention was included along  with the drug to treat overweight or obese 
people. The total number of fatal and non-fatal CHD events avoided in five years of analysis was 
estimated as 3.49 in Finland, 4.18 in Germany, 4.49 in Switzerland, and 1.96 in the UK per 1,000 
people, while the average number of diabetes cases avoided was 3.0. In an Italian obese population, 
another drug, orlistat, was studied [79]. The same drug combined with a low-calorie diet for obese 
patients was also assessed for the whole Dutch population, estimated over a lifetime horizon using the 
RIVM  chronic  disease  model  [80];  the  combined therapy was estimated  to  produce  an  additional 
34,000 life years. 
A  weight-reduction  drug,  rimonabant,  was  compared  with  lifestyle  intervention  [81]  using  a 
decision tree with five arms, i.e., treatment options. Two years‘ treatment with rimonabant combined 
with  lifestyle  intervention  produced  the  most  cost-effective  option.  Employing  a  Markov  model,  
Roux et al. [82] compared four weight-loss strategies in overweight and obese women. The strategies 
were diet only, diet + pharmacotherapy (orlistat), diet + exercise, and diet + exercise combined with 
behavior therapy. The weight-loss intervention consisted of six months of intervention followed by a 
six-month  maintenance  program.  Diet  +  exercise  combined  with  behavior  modification  was  the  
best strategy.  
When statin drugs and cholesterol-lowering diets were compared with no interventions for patients 
with a high cholesterol level using the CHD Policy Model over a 30-year period, both interventions 
produced much higher cost/QALY in the primary prevention [83]. This may be because statins were 
expensive  at  the  time  (1997),  before  they  were  available  as  generics.  In  another  study  [84],  four 
strategies for preventing or delaying diabetes, i.e., screening for early detection, screening + lifestyle 
intervention, screening + lifestyle + pharmacological intervention, and no screening, were compared 
with  a  hybrid  model  using  a  three-arm  decision  tree  and  seven-state  Markov  model.  Screening 
followed by lifestyle intervention was the most cost-effective strategy. 
All pharmacological studies included a short-term trial period (six months to one year) extrapolated 
to a five- or ten-year time horizon, except one that employed a lifetime horizon [80]. One issue in 
pharmacological  interventions  was  weight  regain  after  intervention  end;  the  National  Institute  of 
Clinical Excellence (NICE) recommendation [85] on assumed uniform weight regain over a three-year 
period had not been taken into consideration. Furthermore, though all drugs had some side effects, the 
related loss of quality of life was not considered. We agree with previous review findings that the main 
sources of uncertainty in pharmacological interventions are weight-loss sustainability, utility gains 
associated with weight loss, extrapolation of long-term benefits from short-term trials, dropout rate, 
side effects, and bias towards the funding authority [86].  
Surprisingly, all effectiveness data for drug interventions are based on literature reviews, except 
data from the study [79] reporting the highest ICER (75,300 €/QALY). When lifestyle interventions 
are compared with pharmacotherapy, lifestyle interventions are more effective, i.e., in survival years, 
disease-free time, and quality-adjusted life expectancy [82], indicating that lifestyle interventions are 
better options for preventing lifestyle diseases.   
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3.2. Decision Analytic Models (DAM) 
 
Of 46 studies, 31 employed DAM: six used decision trees, 20 used Markov models, and one used 
an Archimedes model (Table 6). One article used both a Markov model and a decision tree [84], one 
used  four  Markov  models  [60],  one  used  an  Archimedes  model  [44],  and  two  used  a  life  table 
approach. A decision tree is a simple visual representation of possible options and their consequences. 
Decision  trees  start  with  the  options,  each  of  which  branches  out  to  explore  all  potential  health 
outcomes  and  their  respective  probabilities  and  costs.  In  Markov  models,  participants  move  from 
defined health states (Markov states) in discrete time periods (Markov cycles). Each health state incurs 
particular costs and health consequences [18]. It is common to use a previously developed model; all 
the  
Dutch [63,75,80] studies used the RIVM chronic disease model adapted to the study objectives, while 
the  CHD  Policy  Model  [61,83]  and  the  CDC  diabetes  model  [38,40,41]  have  been  used  in  
many studies. 
Philips et al. [92] emphasized several issues for good practice in modeling: model structure; data 
employed, i.e., inputs (costs) and outcomes (health benefits); and model consistency or validity. For 
Markov models, the structure generally concerns the health states included, as inclusion of costly 
diseases (e.g., stroke due to diabetes in diabetes progression models) might overestimate the long-term 
results. Another example is that the RIVM chronic disease model [63] included certain types of cancer 
absent from another model [46], although both models were developed for overweight and obesity. 
The effectiveness data were taken from a single trial or literature review. For most models, the 
model population was a hypothetical cohort but, when the effectiveness of a trial was transferred to 
different country settings, the model population was often matched with the study population; for 
example,  the  survey  population  from  the  US  National  Health  and  Nutrition  Survey  [41]  and  the 
participants in the German KORA study were matched with the DPP participants [42], and similarly in 
three other studies [39,44,60]. 
Two  types  of  cost  data  were  included  in  the  models:  cost  of  intervention  and  cost  of  disease 
avoided. Some studies estimated the intervention cost from a clinical trial [91], some calculated the 
cost retrospectively [71], and some based the cost on national administrative databases [65], expert  
opinion [73], or even modeler opinion. The avoided disease costs were country specific if available; 
otherwise, the applicable data were taken from other countries. The model outcomes were QALYs, 
DALYs, LYG, or other measures of health. Different countries were found to have used different 
instruments  when  estimating  QALYs:  QWB-SA  was  used  for  the  DPP  models,  European  studies 
frequently used EQ-5D, while Finnish and Australian studies preferred their own instruments (i.e., 
15D and Aqol). Models are subjected to internal validation (i.e., comparing model output with the data 
used in building model), external validation (i.e., checking whether the model output is consistent with 
the disease outcome and epidemiological data), and between-model validation (i.e., comparing the 
estimated intervention outcome with the outcomes of other models based on similar assumptions and 
addressing similar diseases) [92,93], as model quality depends largely on input data quality [94]. No 
studies  provided  any  details  on  all  the  three  types  of  validation.  However,  in  modeling,  it  is 
recommended that a technical report [19], i.e., a detailed description of all assumptions and parameter Int. J. Environ. Res. Public Health 2010, 7                 
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values used to construct the model, be provided. Not all model studies mentioned technical reports, 
though some provided supplementary materials. Int. J. Environ. Res. Public Health 2010, 7                 
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Table 6. Characteristics of decision analytic model (DAM). 
First author, 
year 
Model  Health states in model  Population 
Time 
horizon 
Risk factor  Effectiveness data 
Effectivenes
s measure 
Methods/ 
Instruments 
Ackermann ‘06 
 [40] 
Markov 
model (CDC) 
Nephropathy, neuropathy, retinopathy, 
coronary heart disease and stroke 
DPP participant  Lifetime  From DPP  Single study (DPP)  QALY  QWB 
Ara ‘07 
[76] 
Decision tree  CHD, diabetes  Hypothetical  5 years 
CHD from Framingham 
and others from literature 
SAT clinical trial 
and literature 
review 
QALY  SF-36 
Bemelmans 
‘08 
[63] 
Markov 
model 
(RIVM-
CDM) 
CHD, T2DM, certain cancers, low-back pain, 
arthritis 
Entire Dutch population  Lifetime 
Age, body weight, physical 
activity, disease state, risk 
factor classes 
Two studies from 
Netherlands 
QALY/ 
LYG 
Not clear 
Booth ‘07 
[64] 
Markov 
model 
11 states: BPG0, BPG1, BPG2, BPG3, CHD, 
CVE, CHD&CVE, CVE&CHD, CHD death, 
other death, CVE death 
Representative Finnish 
population 
10–40 years  Framingham 
National Health 
Examination 
Survey 
LYG, 
QALY 
15D 
Brennan ‘06 
[77] 
Decision tree  CHD, Diabetes 
Hypothetical German 
population of 1,000 
5 years  Framingham  Literature review  QALY  SF-36 
Brown 
‘07 [66] 
Life table 
approach 
Hypertension, hypercholesterolemia, T2DM, 
CVD, stroke 
Single study population  24 years 
Life table Framingham 
model 
Single study 
(CATCH) 
QALY  Not clear 
Caro ‘04 
[43] 
Markov 
model 
IGT, NGT, T2DM, death 
Hypothetical population  
of 1,000 
10 years  Literature review 
DPP, DPS and 
STOP-NIDDM for 
acarbose 
LYG  - 
Colagiuri ‘08 
[65] 
Decision tree  15 health states 
Entire Australian 
population aged 45–74 
10 years 
(2000–2010) 
Not clear 
DPP, DPS and 
UKPDS 
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Dalziel 
‘07 [60] 
4 Markov 
models 
1. Cardiac model: free of further events, minor 
events, AMI, major events, stroke, and death; 
2. Diabetes model: DM, IGT, NGT, death; 
3.Fruit & vegetable model: Success, failure, 
death. 4. BMI model: Normal, overweight, 
obese, and death 
Entire Australian 
population 
20 years  
(5 years for 
2 studies) 
-  Literature review  QALY 
SF-36, EQ 
5D, AqoL, 
Time 
tradeoff 
Dalziel 
‘06 [55] 
Markov 
model 
3 states: physically active, physically inactive, 
and dead 
Hypothetical cohort 
(matched with trial 
population) 
Lifetime  Literature review  Single study  QALY  SF-36 
Eddy ‘05 
[44] 
Archimedes 
model 
Diabetes, hypertension, asthma, CHF, 
retinopathy, stroke, nephropathy, neuropathy, 
death 
 
Hypothetical population 
(matched with DPP) 
5–30 years  -  Literature review  QALY  QWB-SA 
Galani 
‘08 [46] 
Markov 
model 
Overweight, hypertension, diabetes, 
hypercholesterolemia, stroke, CHD 
Hypothetical Swiss 
population of 10,000 
65 years 
(25–85) 
Framingham  DPS 
QALY 
& LYG 
Not clear 
Galani 
‘07 [47] 
Markov 
model 
Overweight, hypertension, diabetes, 
hypercholesterolemia, stroke, CHD 
Hypothetical Swiss 
population of 10,000 
Lifetime  Framingham  DPS  QALY  Not clear 
Gillies 
‘08 [84] 
Markov 
model and 
decision tree 
7 states: NGT, IGT diagnosed, IGT 
undiagnosed, T2DM (screening detected, 
clinically detected, undiagnosed) 
Hypothetical population 
starting age 40 
50 years  Literature review  Literature review  QALY  EQ 5D 
Hampp 
‘08 [81] 
Decision tree 
CHD & diabetes, only CHD, only diabetes, no 
CHD, and no diabetes 
Hypothetical population  5 years   
Three published 
clinical trials 
QALY 
Literature, 
VAS, TTO 
Herman 
‘05 [38] 
Markov 
model (CDC) 
Nephropathy, neuropathy, retinopathy, CHD, 
and stroke 
Hypothetical population  Lifetime  CDC model risk factors  Literature review  QALY  QWB-SA 
Hoerger 
‗07 [41] 
Markov 
model (CDC) 
Three modules: screening, prediabetes, and 
diabetes 
Hypothetical population 
Up to 75 
Years 
CDC model risk factors  Literature review  QALY  QWB-SA 
Iannazzo ‘08 
[79] 
Markov 
model 
3 states: obese without diabetes, obese with 
diabetes, and death 
Hypothetical Italian 
population 
10 years  Framingham  Single study (RCT)  QALY  Not clear Int. J. Environ. Res. Public Health 2010, 7                 
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Icks ‘07  
[42] 
Decision tree  Screening, prediabetes, and diabetes 
German population from 
KORA study 
3 years  -  DPP 
incidence of 
diabetes 
avoided 
- 
Jacobs- van ‘07  
 [75] 
Markov 
model 
(RIVM-
CDM) 
Diabetes, CVDs, cancers, musculoskeletal 
disease 
Dutch population 
Lifetime  
(70 years) 
Literature review  Literature review  QALY  Not clear 
Lindgren ‘07 
[48] 
Markov 
model 
IGT, MI, stroke, MI 2nd y, stroke 2nd y, 
T2DM, death 
A 60-year-old Swedish 
cohort 
6 years  DPS, UKPDS  DPS  QALY  EQ-5D 
Lindgren ‘03 
[73] 
Markov 
model 
10 states: without CVD, 1st and 2nd y of UA, 
MI, UMI, angina, death 
A 60-year-old Swedish 
cohort 
Lifetime 
(60–109 
years) 
Framingham  Single study (RCT)  LYG  - 
Palmer 
‘04 [39] 
Markov 
model 
IGT, T2DM, deceased 
Hypothetical population 
(matched with DPP) 
Lifetime  DPP 
DPP and literature 
review 
LYG  - 
Prosser 
‘00 [83] 
Markov 
model (CHD 
Policy 
Model) 
3 models at the same time (AP, MI, cardiac 
arrest, coronary revascularization) 
Women and men  
35–84 years 
30 years 
HDL, LDL, age group, sex, 
smoking status, diastolic 
BP 
Literature review  QALY  SF-36 
Roux ‘06 
[82] 
Markov 
model 
AP, MI, cardiac arrest 
Hypothetical 10,000 
obese women 
Lifetime  Framingham  Literature review  QALY, LYG  Not clear 
Roux ‘08 
[54] 
Markov 
model (CDC 
MOVE 
model) 
10 health states, 4 levels of physical activity, 
CHD, ischemic stroke, T2DM, breast cancer, 
colon cancer 
Hypothetical USA 
population 
40 years  -  Literature review  LYG, QALY  QWB-SA 
Salkeld ‘97 
[70] 
 
Model 
(Johannesson 
et al) 
CHD (MI, UMI, AP, coronary insufficiency, 
sudden death), stroke, non-CVD death 
Hypothetical population  1 year  Framingham 
One Australian trial 
and literature 
review 
QALY, 
LYS 
TTO Int. J. Environ. Res. Public Health 2010, 7                 
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Tice ‘01 
[61] 
Markov 
model (CHD 
Policy 
Model) 
3 models (AP, MI, cardiac arrest, coronary 
revascularization) 
Entire US population  10 years  Framingham  Literature review  QALY  TTO 
van Baal ‘08 
[80] 
Markov 
model 
(RIVM-
CDM) 
CHD, stroke, diabetes, osteoarthritis, low back 
pain, some cancers 
Entire Dutch population  80 years  -  Literature review  QALY 
Person 
tradeoff 
Wang ‘03 
[68] 
Life table 
approach 
-  Single trial population  40 years  Literature review 
Single trial (Planet 
Health) and others 
QALY  Not clear 
Warren ‘ 
04 [78] 
Decision tree  CHD, diabetes 
Hypothetical 1000 
population 
5 years  Framingham  Literature review  QALY  SF-36 
Abbreviations: 15D, 15 dimensions; AMI, acute myocardial infarction; AP, angina pectoris; BP; blood pressure; BPG, blood pressure group; CDC, Centre for Disease Control and 
Prevention; CHD, coronary heart disease; CHF, coronary heart failure; CVE, cerebrovascular events; DPP, Diabetes Prevention Program; DPS, Diabetes Prevention Study; EQ-5D, Euro Qol 
5 Dimension; HDL, high-density lipoprotein cholesterol; IGT, impaired glucose tolerance; LDL, low-density lipoprotein cholesterol; LYG, life years gained; MI, myocardial infarction; 
NGT, normal glucose tolerance; QALY, quality-adjusted life years; QWB, quality of well being scale; QWB-SA, quality of well being scale—self-administered; RIVM-CDM, RIVM 
chronic disease model; SF-36, Short Form 36; T2DM, type 2 diabetes mellitus; TTO, time tradeoff; UA, unstable angina; UKPDS, United Kingdom Prospective Diabetes Study; UMI, 
unrecognized myocardial infarction; VAS, visual analogue scale. Int. J. Environ. Res. Public Health 2010, 7                 
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3.3. Long-Term Effectiveness of Lifestyle Intervention 
 
An important expectation in a lifestyle intervention is long-term adherence to the changed behavior, 
either  the  change  in  dietary  habit  or  the  increase  in  physical  activity.  A  key  issue  in  economic 
evaluations of such interventions is to link short-term evidence from clinical trials or epidemiological 
data  to  the  long-term  benefits  of  changed  behavior.  When  considering  long-term  effectiveness, 
researchers  often  analyze  different  scenarios  with  optimistic  or  pessimistic  assumptions  and  then 
assess  the  uncertainty  in  sensitivity  analyses.  However,  there  is  some  indecision  concerning  the 
optimistic  and  pessimistic  assumptions  or  the  best-  and  worst-case  scenarios.  The  base  case 
assumptions  used  in  the  lifestyle  interventions,  alternatives  used  for  sensitivity  analyses  and  the 
changes in baseline results of the sensitivity analysis are highlighted in Table 7. 
The assumption about whether the intervention effect is maintained after the intervention (or trial) 
dramatically affects the cost-effectiveness ratio or result. We believe it is pessimistic to assume that 
the effectiveness will persist only as long as the intervention period, as has been done in several  
studies [39,63,65,70,75], and too optimistic to assume that the effectiveness will persist until death, as 
is done elsewhere [71,73]. For example, one study assuming that the effectiveness would persist only 
for  the  intervention  period  (pessimistic  assumption)  reported  a  result  of  152,000  AU$/QALY; 
however, if the effectiveness had been assumed to persist one additional year, the result would be  
6,600 AU$/QALY [70]. On the other hand, if intervention effectiveness is assumed to be one year 
(pessimistic assumption), instead of lifelong the cost-effectiveness ratio would be 10 times higher than 
the base case (lifelong effectiveness) result [71]. In the case of DPP, some researchers assumed that 
the intervention and its effectiveness would persist until the participants developed diabetes or died—
an  optimistic  assumption  [38,40,41,44].  On  the  other  hand,  other  researchers  assumed  that  the 
effectiveness would decline by 20% each year [41] and 50% over the total period [38,40]. Reducing 
the  effectiveness  by  20%  resulted  in  1.5  times  [41]  and  almost  seven  times  [38]  higher  total  
cost-effectiveness ratios than in the base case analysis. In the DPP trial, the lifestyle intervention was 
58% effective, which Caro et al. [43] used for the base case analysis with 30% as the worst- and 70% 
as the best-case value. With 70% effectiveness, the result was dominant, i.e., the intervention is more 
effective and less costly than the alternative. Roux et al. [82] assumed in the base case analysis that 
only 20% of participants would maintain the changed behavior in the long term, with optimistic and 
pessimistic assumptions, i.e., over 40% and under 10%, respectively, which resulted in estimates four 
times higher or half the base case cost-effectiveness ratio. Van Baal et al. [80] assumed that 23% of 
the  intervention  weight  loss  would  persist  in  the  long  run  as  the  pessimistic  assumption,  with 
optimistic values of 50% or 100% maintained weight loss. With 100% maintained weight loss, the  
cost-effectiveness ratio was almost three times lower than the base case value. 
When long-term effectiveness issues are addressed using univariate sensitivity analysis, the changes 
in results are obvious. However, when probabilistic sensitivity analysis is performed, the changes in 
results due to effectiveness uncertainty are not clearly distinguished, as seen in two studies by the 
same author [46,47]. The assumptions in these studies were that weight loss (the intervention effect) 
would persist up to six years and the regain process would take four more years. After 10 years, the 
weight of the participants would be same as at the intervention start. Int. J. Environ. Res. Public Health 2010, 7                 
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Table 7. Uncertainty around long-term effectiveness of lifestyle interventions. 
First author, 
year 
Base case Assumption 
Intervention 
period 
Sensitivity 
analysis 
Sensitivity analysis assumption  Base case result 
Changes in result due to 
sensitivity analysis 
Ackermann ‘06 
[40] 
Intervention and effects continued until 
patients developed disease or died 
-  Univariate  Intervention will be only 50% effective  1,288 US$/QALY  Not clear 
Ara ‘07 
[76] 
Weight loss regained within 5 years of 
intervention 
1 year  Univariate  Higher and lower rate of weight regain 
2,149 €/QALY for 
Finland,13,707 €/QALY for 
Germany,10,734 €/QALY for 
Switzerland, 11,811 €/QALY 
for UK 
14% around the ICER for all 
countries 
Bemelmans ‘08 
[63] 
Effect stops after intervention period  1 year  Univariate  The effect varies 1–4 percentage points  5,700 €/QALY  5,600 €/QALY to 9,900 €/QALY 
Brennan ‘06 
[77] 
Weight loss regained within 5 years of 
intervention 
1 year  Univariate 
Weight regain equals upper and lower CI, 
Delay weight regain by 3 months and 6 
months 
13,706 €/QALY 
 
15,747 and 11,830 for CI, 
10,404 and 8,235 for 3 months‘ 
and 6 months‘ delay 
Caro ‘04 
[43] 
Lifestyle intervention will be 58% 
effective 
5 years  Univariate 
Lifestyle intervention will be 30% and 
70% effective 
ICER 749 CA$/LYG 
9,445 CA$/LYG for 30% and 
―dominant‖ for 70% 
Colagiuri ‘08 
[65] 
The effect will persist as long as 
intervention continues 
10 years  Univariate  Complications reduced to half  50,000 AU$/DALY  Approx. 86,000 AU$/DALY 
Dalziel ‘06 
[55] 
Effect returns to baseline at 4 years 
3 weeks to 
2 years 
Univariate, 
probabilistic 
Intervention effect returns to baseline at 1 
years, 5 years, 10 years 
2,053 NZ$/QALY 
10,381 NZ$/QALY (for 1 year), 
1,663 NZ$/QALY (for 5 years), 
1,160 NZ$/QALY (for 10 years), 
At 10,000 NZ$ WTP, 97% chance 
of being cost-effective 
Eddy ‘05 
[44] 
The effect will persist as long as the 
intervention continues 
  Univariate 
20% lower and 20% higher effect on 
QALY 
143,000 from healthcare and 
62,600 from societal 
(US$/QALY) 
178,000 and 120,000 from 
healthcare, 78,000 and 52,000 
from societal 
Finkelstein ‘06  
 [71] 
Effect will persist until death  1 year  Univariate  Effect will persist only 1 year  4,400 US$/LYG  44,500 US$/LYG Int. J. Environ. Res. Public Health 2010, 7                 
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Galani ‘07 
[47] 
 
Weight loss maintained for 6 more 
years and 4 years to regain the weight. 
After 10 years the weight reaches the 
baseline 
3 years 
Probabilisti
c 
- 
64 CHF/QALY for female and -
354 CHF/QALY for male in 
borderline group 
At 1,000 CHF WTP,  
99% chance of being cost-
effective 
Galani ‘08 
[46] 
The weight loss and CVD risk 
reduction persist for 6 more years and 4 
years to regain the weight. After 10 
years the weight reaches the baseline 
3 years 
Probabilisti
c 
- 
ICER 4,358 CHF/QALY 
(Female) and 2,189 
CHF/QALY (Male) 30 years 
old and overweight 
At 4000 CHF WTP lifestyle 
intervention has 45% (Female) 
and 75% (Male) chance of being 
cost-effective 
Gillies ‘08 
[84] 
Intervention and effects persisted until 
patients died 
- 
Univariate, 
probabilistic 
-  6,242 £ /QALY 
At £  20,000 WTP, 99% chance of 
being cost-effective 
Hampp ‘08 
[81] 
Weight loss persists 1 year  1–2 years 
Univariate, 
probabilistic 
Weight loss persists 0.5–3 years  52,936 US$/QALY 
35,000 (0.5 years) and 62,000 (3 
years). At US$ 50,000 WTP 
40.2% chance of being  
cost-effective 
Herman ‘05 
[38] 
Effect will persist until participants 
contract disease 
- 
Univariate, 
probabilistic 
The effect will decline by 50% and 20%  1,100 US$/QALY  3,102 and 7,886 US$/QALY 
Hoerger ‘07 
[41] 
Intervention continued until patients 
developed disease or died 
-  Univariate 
The risk reduction from DPP will decline 
by 20% each year 
Strategy one,8,181 US$/QALY; 
Strategy two, 9,511 US$/QALY 
Strategy one, 13,179 US$/QALY; 
Strategy two, 14,387 US$/QALY 
Jacobs-van ‘07 
[75] 
Effect stops after intervention period  5 years  Univariate  No sensitivity analysis in this issue  -  - 
Lindgren ‘07 
[48] 
Effect stops after intervention period  4 years  Univariate  Effect of intervention persists for 2 years  2363 €/QALY  Dominant 
Lindgren ‘03 
[73] 
Risk reduction effect will persist 
lifelong (109 y) or the effect will persist 
only 2 years 
6 months  Univariate  - 
ICER 127,065 SEK/LYG with 
declining effect and 141,555 
SEK/LYG with remaining 
effect 
- 
Palmer ‘04 
[39] 
The effect will persist as long as 
intervention continues 
3 years  Univariate  The effect will persist lifelong 
24.56 year improved life 
expectancy 
25.21 year improved life 
expectancy Int. J. Environ. Res. Public Health 2010, 7                 
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Roux ‘06 
[82] 
Long-term maintenance will be 20%    Univariate 
Long-term maintenance will be ≤10% and 
>40% 
12,600 US$/QALY 
50,000 for 10% and 6,000 for 40% 
maintenance US$/QALY 
Roux ‘08 
[54] 
33% to 50% decline of benefit after 
intervention 
12 months 
Univariate, 
probabilistic 
- 
ICER 14,286 to 68,557 
US$/QALY 
At 200,000 WTP, 100% chance of 
being cost-effective 
Salkeld ‘97 
[70] 
Effect stops after intervention period.  1 years  Univariate 
Effect will persist 1 year more in high-risk 
group 
ICER 152,128 AU$/QALY for 
males 
ICER 6,589 AU$/QALY 
van Baal ‘08 
[80] 
23% of the weight loss achieved after 1 
year will be maintained in the long run 
1 year 
Univariate, 
probabilistic 
50% and 100% weight-loss maintenance 
in both interventions  
ICER 17,900 €/QALY for  
low-calorie diet and  
58,800 €/QALY for orlistat +  
low-calorie diet 
ICER range  
8,100–17,800 €/QALY for  
low-calorie diet and  
24,100–18,700 €/QALY for  
low-calorie diet + orlistat 
Warren ‘04 
[78] 
The weight regain to baseline will 
completed within 50 months for 
participants and 18 months for placebo 
group 
1 year 
Univariate, 
multivariate 
Weight regain equals upper and lower CI  ICER 4,780 £ /QALY  4,828 £ /QALY and 4,731£ /QALY 
Abbreviations: CI, confidence interval; ICER, incremental cost-effectiveness ratio; LYG, life years gained; QALY, quality-adjusted life years; WTP, willingness to pay; y, years. Int. J. Environ. Res. Public Health 2010, 7                 
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For  the  pharmacological  weight  reduction,  the  weight  regain  process  was  often  assumed  to  be 
completed within five years of a one-year intervention [76-78], and a confidence interval (CI) was 
used  in  the  sensitivity  analysis.  Assuming  one  year  of  sustained  weight  reduction  [81]  made  the  
cost-effectiveness ratio unfavorable. Nevertheless, if the weight loss persisted for three years, the value 
was in the cost-effective range (under US$ 50,000); using the probabilistic sensitivity analysis, the 
authors  demonstrated  that  at  US$ 50,000 willingness  to  pay,  the intervention had 40% chance of  
being cost-effective. 
 
4. Discussion 
 
It is difficult to compare the results of one cost-effectiveness analysis with another, because of 
differences in methodology, types of costs included, outcomes, and population groups and related 
baseline  risk.  There  may  also  be  differences  in,  for  example,  healthcare  systems,  incentives  to 
healthcare  professionals  and  institutions,  clinical  practices,  population  values,  availability  and 
accessibility of technologies, and currency purchasing power. 
Establishing  that  an  intervention  is  cost-effective  is  still  problematic,  since  the  threshold  for  
cost-effectiveness, i.e., decision maker willingness to pay, is controversial. NICE in the UK uses a 
cost-effectiveness threshold range of £ 20,000 to £ 30,000 per QALY gained [95,96]. In contrast, there 
are  no  official  guidelines  for  the  USA  and  Australia,  though  US  researchers  frequently  employ  
50,000  US$/QALY  [97],  while  Australian  researchers  use  50,000  AU$/DALY  [98]  as  thresholds. 
WHO  has  recommended  that  interventions  be  considered  cost-effective  if  costs  per  DALY  are  
1–3  times  GDP  per  capita  [99].  Some  argue  that  cost-effectiveness  thresholds  may  be  too  
high [100,101], others argue that they are too low [102,103], while still other claim the well-accepted 
US$ 50,000 threshold is misused [104]. Moreover, one review of cost-effectiveness analyses suggested 
that published studies tended to report results below US$ 50,000 per QALY [105]. 
Some  recent  DAM  guidelines  emphasize  that  models  should  be  kept  as  simple  as  possible, 
providing  they  capture  all  essential  parts  of  the  disease  processes,  including  effects  of  health 
technologies, to help policymakers make informed decisions [93,106-108]. Certain standard criteria 
should be considered when developing a model, in what is often referred to as validating [109,110] and 
calibrating [94,111] a model. It is not always possible to apply all recommendations in one model, so 
researchers often make tradeoffs between model accuracy and transparency. Transparency refers to the 
understandability of the logical arguments of a model, to enable it to be reproduced; accuracy refers to 
a model‘s ability to capture real-life situations [112]. Balance between accuracy and transparency is 
difficult to obtain in a model: as a model is made more accurate, its complexity increases, which in 
turn reduces its understandability to decision makers. Accordingly, some researchers emphasize model 
transparency [93], whereas others argue that accuracy should be paramount [112]. 
When an intervention leads to significant health benefits in comparison with the comparator, the 
ICER is supposed to be low. For example, when a physical activity prescription was effective in a 
target population in New Zealand, the ICER was very low [55]; however, when interventions had no 
significant  impacts  on  target  groups,  as  seen  in  two  studies  of  video-based  lessons  [62,70],  the 
interventions  were less cost-effective. Another aspect is the analytical time horizon: if it is short, 
health benefits are limited, likely resulting in high ICERs. DPP provides a good example; the ICERs Int. J. Environ. Res. Public Health 2010, 7                 
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for the short-term, three-year trial period [37] are much higher than those for the long-term lifetime  
analysis [38]. The age of the target population might also affect ICERs, as young target groups might 
achieve  greater  health  benefits  than  older  groups.  Interventions  for  school  children  are  very  
beneficial [66], as are those starting at ages around 20 [54,75,76]. In contrast, interventions starting 
later in life, such as those examined by Lindgren et al. [48,73], who use 60 years as the starting age, 
result in much higher ICERs. ICERs are also affected by the risk level of the population. When the risk 
is high, as it is among the overweight or obese, the potential health gains from interventions are higher; 
this was illustrated nicely in two articles [46,47]. 
Naturally, intervention cost drastically affects cost-effectiveness, as is obvious in the DPP trial of 
costly  face-to-face  vs.  cheaper  group-based  counseling.  Another  aspect  is  whether  screening  for  
high-risk individuals is included in the interventions. Icks et al. [42] reported that diabetes screening 
comprises 36% of the total intervention cost, which was one reason for the high ICER. The costs of 
developing a website [91] to motivate participants to increase physical activity can also make the  
cost-effectiveness ratio unattractive. 
The cost-effectiveness ratio of our reviewed studies range from 46 AU$/QALY [55] for fruit and 
vegetable  intake  to  as  high  as  143,000  US$/QALY  for  DPP  lifestyle  intervention  [44].  
Community-based interventions seem to have low cost-effectiveness ratios [63,69,75] ranging from 
1,100 to 5,000 Euro/QALY. School-based interventions are also attractive, at 900 US$/QALY [66] 
and  4,305  US$/QALY  [68],  as  are  targeted  screening  followed  by  lifestyle  interventions  [41,42]. 
However,  any  targeted  intervention  could  be  made  more  favorable  by  dealing  with  the 
abovementioned issues (i.e., risk level in target groups, intervention cost, intervention effectiveness, 
and starting intervention at young age) and adjusting the assumptions of the model parameters. So, 
cautious interpretation is required to generalize the results. 
Icks et al. [42] argued that  we lack information on the long-term effects of T2DM prevention 
interventions, and lack valid data regarding the natural course of T2DM from early onset to death. 
However, recent studies have examined the long-term effects of the DPP [31], Da Qing [32], and DPS 
trials [113]. This suggests that it is time to update models, so they are based on recent epidemiological 
data. Nevertheless, if long-term clinical effectiveness data are unavailable, the only way to explicitly 
explore the future effect of an intervention after its completion is by modeling; that modeling permits 
such exploration should be considered one of its major strengths, not a weakness [114]. The validity of 
long-term  effectiveness  assumptions  would,  however,  benefit  from  some  kind  of  consensus  and 
harmonization, apart from the recommendation to perform relevant sensitivity analyses. 
This review is limited in that it is not systematic and in that it omits studies not included in the 
NHS-EED database, such as monographs, some gray literatures, and book chapters. Smoking cessation 
is an important lifestyle intervention but, as the topic has been subject to extensive review [115,116], it 
is  excluded  here.  Dieting  is  a  popular  lifestyle  intervention,  but  we  found  no  articles  focusing 
specifically on dieting as a weight-loss intervention. However, one objective of DPP-like interventions 
was to reduce weight by 7% using both diet and physical activity interventions. Roux et al. have used 
diet as a sole intervention for weight loss in women [82], but three other weight-loss strategies were 
also  addressed  at  the  same  time.  Another  study  [73]  used  a  sole  dietary  intervention,  though  the 
objective was not weight loss. The ICERs in the studies have not been converted to a common price 
year,  since  there  is  no  fixed  cost-effectiveness  threshold,  and  the  ICERs  reported  depend  on  the Int. J. Environ. Res. Public Health 2010, 7                 
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comparators,  which  vary  widely  in  the  studies  reviewed.  The  actual  incremental  costs  per  health 
outcome reported are better regarded as indications of cost-effectiveness. Another important limitation 
is that none of the three available quality checklists [117-119] is used for assessing article quality, 
partly because the checklists were developed only recently [117,119], after several of the included 
studies. Furthermore, a recent study states that the quality appraisals depends on the researchers and 
not on the checklists [120], as ICERs are unlikely to be affected by a single factor but rather by a 
combination of several. 
This  is  the  first  study,  to  our  knowledge,  to  include  dietary  and  physical  activity  lifestyle 
interventions that affect T2DM and/or CVDs, with a special focus on DPP-type interventions. A recent 
study by Anderson [121] questioned the use of systematic reviews of economic evaluations, partly 
because the interplay of 26 factors makes the results of cost-effectiveness analyses vary depending on 
setting and location [122]; as well, 14 factors had to be considered to ensure transferability of results 
from one country to another [123]. On the other hand, there are three good reasons to review economic 
evaluations: (1) to study the development of new decision models; (2) to identify the most relevant 
studies for a particular decision making context; and (3) to identify the ―how and why‖ causality of 
interventions  that  are  cost-effective  in  certain  settings  but  not  in  others,  including  the  principal 
economic tradeoffs in particular decision areas. This review identifies several new decision models, 
such as models of screening for diabetes and ensuing interventions [84], a model of multiple behavior 
modification [82], a model of cardio–metabolic disorders [46], and a model used for DPS [48] that 
differs from older models, such as the CHD Policy Model [61,83], the Johannesson model [70], and 
the CDC model [38,40-41]. The MOVE model [54] is a new updated physical activity model, differing 
from a previous model developed by NICE [124]. The models developed to study national plans of 
action/policy are  new and  advanced, and economic evaluations of national action plans may well 
constitute  a  new  research  area  [63-65].  The  economic  tradeoff  in  intervention  options  is  well 
demonstrated in DPP-like studies, in which intervention provision (individual vs. group counseling) 
and  different  country  settings  (USA  vs.  India)  are  key  factors  [37,45].  Tradeoffs  have  also  been 
identified  in  Dutch  studies  in  which  community-based,  high-cost/low-effectiveness  intervention  is 
compared  with  healthcare-based  highly  effective  low-cost  intervention  [63,75].  The  explanatory 
theory-building aspects of how and why an intervention works are hard to establish in public health 
interventions because of the complex and inherent interplay of several health determinants. Moreover, 
the reviewed studies were not informative enough in explaining how the intervention, cost, and health 
effect outcomes are affected by different configurations of input variables (e.g., patient characteristics 
and  context)  to  build  such  theory  [121].  However,  it  was  found  that  using  different  modeling 
techniques with different assumptions leads to different results, as in the Archimedes model [38] and 
the Markov model [44] in the DPP trial. 
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5. Conclusions 
 
We believe that demand for economic evaluations will continue, because of the need to assess the 
growing number of interventions available to prevent and treat diseases. Economic evaluations of 
public  health  programs  are  still  comparatively  new  and  might  differ  in  some  respects  from 
conventional  economic  evaluations  [36,125].  Further  work  is  also  needed  to  determine  the  
cost-effectiveness  of  interventions  in  disadvantaged  populations  and  to  examine  the  related  issue  
of equity. 
Widespread implementation of lifestyle interventions in high-risk groups to prevent T2DM and 
CVD has no obvious drawbacks. Furthermore, as lifestyle interventions also reduce the risk of other 
chronic diseases, including certain forms of cancer, they have broader benefits for health. Unlike drug 
treatments, lifestyle interventions have few side effects. The use of DAMs in economic evaluations 
does not change the fact that cost-effectiveness analysis cannot incorporate all the values and criteria 
relevant to health policy decisions; it can, however, help to inform decisions in a direct manner.  
Lifestyle interventions appear cost-effective in reducing the long-term risk of T2DM and CVD. It is 
even  cost-effective  to  screen,  either  targeted  or  universally,  for  diabetes  and  CVD.  Combined 
interventions, for example, diet and physical activity, are more beneficial than sole dietary or physical 
activity  interventions.  Interventions  starting  from  school-aged  children  or  focusing  on  the  whole 
community are attractive in terms of cost-effectiveness. 
 
References 
 
1.  World Health Organization. Global Strategy on Diet, Physical Activity and Health. Available 
online:  http://www.who.int/dietphysicalactivity/strategy/eb11344/strategy_english_web.pdf 
(accessed on 10 April 2010). 
2.  International Diabetes Federation. http://www.idf.org/. 
3.  American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2007. Diabetes Care 
2008, 31, 596–615. 
4.  Eriksson, K.F.; Lindgarde, F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by 
diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991, 34, 891–898. 
5.  Pan, X.R.; Li, G.W.; Hu, Y.H.; Wang, J.X.; Yang, W.Y.; An, Z.X.; Hu, Z.X.; Lin, J.; Xiao, J.Z.; 
Cao, H.B.; Liu, P.A.; Jiang, X.G.; Jiang, Y.Y.; Wang, J.P.; Zheng, H.; Zhang, H.; Bennett, P.H.; 
Howard, B.V. Effects of diet and exercise in preventing NIDDM in people with impaired glucose 
tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20, 537–544. 
6.  Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes 
with Lifestyle Intervention or Metformin. N. Engl. J. Med. 2002, 346, 393–403. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3187 
7.  Tuomilehto, J.; Lindstrom, J.; Eriksson, J.G.; Valle, T.T.; Hamalainen, H.; Ilanne-Parikka, P.; 
Keinanen-Kiukaanniemi, S.; Laakso, M.; Louheranta, A.; Rastas, M.; Salminen, V.; Aunola, S.; 
Cepaitis,  Z.;  Moltchanov,  V.;  Hakumaki,  M.;  Mannelin,  M.;  Martikkala,  V.;  Sundvall,  J.; 
Uusitupa,  M.;  the  Finnish  Diabetes  Prevention  Study  Group.  Prevention  of  Type  2  Diabetes 
Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N. Engl. J. 
Med. 2001, 344, 1343–1350. 
8.  Ramachandran, A.; Snehalatha, C.; Mary, S.; Mukesh, B.; Bhaskar, A.D.; Vijay, V. The Indian 
Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 
diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006, 
49, 289–297. 
9.  Kosaka,  K.;  Noda,  M.;  Kuzuya,  T.  Prevention  of  type  2  diabetes  by  lifestyle  intervention:  a 
Japanese trial in IGT males. Diabetes Res. Clin. Pract. 2005, 67, 152–162. 
10.  Mensink,  M.;  Feskens,  E.J.;  Saris,  W.H.;  De  Bruin,  T.W.;  Blaak,  E.E.  Study  on  Lifestyle 
Intervention and Impaired Glucose Tolerance Maastricht (SLIM): preliminary results after one 
year. Int. J. Obes. Relat. Metab. Disord. 2003, 27, 377–384. 
11.  Fleming, P.; Godwin, M. Lifestyle interventions in primary care: systematic review of randomized 
controlled trials. Can. Fam. Physician 2008, 54, 1706–1713. 
12.  Groeneveld,  I.F.;  Proper,  K.I.;  van  der  Beek,  A.J.;  Hildebrandt,  V.H.;  van  Mechelen,  W.  
Lifestyle-focused interventions at the workplace to reduce the risk of cardiovascular disease: a 
systematic review. Scand. J. Work Environ. Health 2010, 36, 202–215. 
13.  Haskell,  W.L. Cardiovascular  disease prevention and  lifestyle interventions: effectiveness and 
efficacy. J. Cardiovasc. Nurs. 2003, 18, 245–255. 
14.  Horton,  E.S.  Effects  of  Lifestyle  Changes  to  Reduce  Risks  of  Diabetes  and  Associated 
Cardiovascular Risks: Results from Large Scale Efficacy Trials. Obesity 2009, 17, S43-S48. 
15.  Banta,  H.D.;  de  Wit,  G.A.  Public  health  services  and  cost-effectiveness  analysis.  Annu.  Rev. 
Public Health 2008, 29, 383–397. 
16.  McDaid, D.; Needle, J. Economic Evaluation and Public Health: Mapping the Literature; Welsh 
Assembly, Health Promotion Division: Cardiff, UK, 2006. 
17.  West  P;  Sanderson  D;  Redmond  S;  Taylor  M;  Duffy  S.  In  A  Critique  of  the  Application  of  
Cost-Effectiveness Analysis to Public Health; York Health Economics Consortium: York, UK, 
2003. 
18.  Drummond, M.F.; Sculpher, M.J.; Torrance, G.W.; O'Brien, B.J.; Stoddart, G.L. Methods for the 
Economic Evaluation of Health Care Programmes; 3rd ed.; Oxford University Press: Oxford, UK, 
2005. 
19.  Gold,  M.R.;  Siegel,  J.E.;  Russell,  L.B.;  Weinstein,  M.C.  Cost-Effectiveness  in  Health  and 
Medicine; Oxford University Press: Oxford, UK, 1996. 
20.  Mü ller-Riemenschneider,  F.;  Reinhold,  T.;  Willich,  S.N.  Cost-effectiveness  of  interventions 
promoting physical activity. Br. J. Sports Med. 2009, 43, 70–76. 
21.  Brunner,  E.;  Cohen,  D.;  Toon,  L.  Cost  effectiveness  of  cardiovascular  disease  prevention 
strategies:  a  perspective  on  EU  food  based  dietary  guidelines.  Public  Health  Nutr.  2001,  4,  
711–715. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3188 
22.  Roine,  E.;  Roine,  R.P.;  Rasanen,  P.;  Vuori,  I.;  Sintonen,  H.;  Saarto,  T.  Cost-effectiveness  of 
interventions  based  on  physical  exercise  in  the  treatment  of  various  diseases:  A  systematic 
literature review. Int. J. Technol. Assess. Health Care 2009, 25, 427–454. 
23.  Vijgen, S.M.C.; Hoogendoorn, M.; Baan, C.A.; de Wit, G.A.; Limburg, W.; Feenstra, T.L. Cost 
Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus: A Systematic Literature 
Review. Pharmacoeconomics 2006, 24, 425–441. 
24.  Huang, P.L. A comprehensive definition for metabolic syndrome.  Dis. Model Mech. 2009, 2,  
231–237. 
25.  Zimmet, P.; Magliano, D.; Matsuzawa, Y.; Alberti, G.; Shaw, J. The metabolic syndrome: A 
global public health problem and a new definition. J. Atheroscler. Thromb. 2005, 12, 295–300. 
26.  Ward,  S.;  Jones,  M.L.;  Pandor,  A.;  Holmes,  M.;  Ara,  R.;  Ryan,  A.;  Yeo,  W.;  Payne,  N.  A 
systematic  review  and  economic  evaluation  of  statins  for  the  prevention  of  coronary  events. 
Health Technol. Assess. 2007, 11, 1–160. 
27.  Waugh, N.; Scotland, G.; McNamee, P.; Gillett, M.; Brennan, A.; Goyder, E.; Williams, R.; John, 
A. Screening for type 2 diabetes: literature  review and economic modelling.  Health Technol. 
Assess. 2007, 11, 1–125. 
28.  Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report 
on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007, 30, 1638–1646. 
29.  Coyle, D.; Lee, K.M.; O'Brien, B.J. The Role of Models Within Economic Analysis: Focus on 
Type 2 Diabetes Mellitus. Pharmacoeconomics 2002, 20, 11–19. 
30.  Lindströ m,  J.;  Ilanne-Parikka,  P.;  Peltonen,  M.;  Aunola,  S.;  Eriksson,  J.G.;  Hemiö ,  K.; 
Hä mä lä inen,  H.;  Hä rkö nen,  P.;  Keinä nen-Kiukaanniemi,  S.;  Laakso,  M.;  Louheranta,  A.; 
Mannelin,  M.;  Paturi,  M.;  Sundvall,  J.;  Valle,  T.T.;  Uusitupa,  M.;  Tuomilehto,  J.  Sustained 
reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish 
Diabetes Prevention Study. Lancet 2006, 368, 1673–1679. 
31.  Diabetes  Prevention  Program  Research  Group.  10-year  follow-up  of  diabetes  incidence  and 
weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374, 1677–1686. 
32.  Li, G.; Zhang, P.; Wang, J.; Gregg, E.W.; Yang, W.; Gong, Q.; Li, H.; Li, H.; Jiang, Y.; An, Y.; 
Shuai, Y.; Zhang, B.; Zhang, J.; Thompson, T.J.; Gerzoff, R.B.; Roglic, G.; Hu, Y.; Bennett, P.H. 
The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes 
Prevention Study: a 20-year follow-up study. Lancet 2008, 371, 1783–1789. 
33.  Eriksson, K.F.; Lindgä rde, F. No excess 12-year mortality in men with impaired glucose tolerance 
who participated in the Malmö  Preventive Trial with diet and exercise. Diabetologia 1998, 41, 
1010–1016. 
34.  Pignone,  M.;  Saha,  S.;  Hoerger,  T.;  Lohr,  K.N.;  Teutsch,  S.;  Mandelblatt,  J.  Challenges  in 
Systematic Reviews of Economic Analyses. Ann. Intern. Med. 2005, 142, 1073–1079. 
35.  Gordon, L.; Graves, N.; Hawkes, A.; Eakin, E. A review of the cost-effectiveness of face-to-face 
behavioural interventions for smoking, physical activity, diet and alcohol. Chronic Illn. 2007, 3, 
101–129. 
36.  Weatherly, H.; Drummond, M.; Claxton, K.; Cookson, R.; Ferguson, B.; Godfrey, C.; Rice, N.; 
Sculpher,  M.;  Sowden,  A.  Methods  for  assessing  the  cost-effectiveness  of  public  health 
interventions: key challenges and recommendations. Health Policy 2009, 93, 85–92. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3189 
37.  Diabetes  Prevention  Program  Research  Group.  Within-Trial  Cost-Effectiveness  of  Lifestyle 
Intervention or Metformin for the Primary Prevention of Type 2 Diabetes. Diabetes Care 2003, 
26, 2518–2523. 
38.  Herman, W.H.; Hoerger, T.J.; Brandle, M.; Hicks, K.; Sorensen, S.; Zhang, P.; Hamman, R.F.; 
Ackermann, R.T.; Engelgau, M.M.; Ratner, R.E.; for the Diabetes Prevention Program Research 
Group.  The  Cost-Effectiveness  of  Lifestyle  Modification  or  Metformin  in  Preventing  Type  2 
Diabetes in Adults with Impaired Glucose Tolerance. Ann. Intern. Med. 2005, 142, 323–332. 
39.  Palmer, A.J.; Roze, S.; Valentine, W.J.; Spinas, G.A.; Shaw, J.E.; Zimmet, P.Z. Intensive lifestyle 
changes  or  metformin  in  patients  with  impaired  glucose  tolerance:  Modeling  the  
long-term health economic implications of the diabetes prevention program in Australia, France, 
Germany, Switzerland, and the United Kingdom. Clin. Ther. 2004, 26, 304–321. 
40.  Ackermann, R.T.; Marrero, D.G.; Hicks, K.A.; Hoerger, T.J.; Sorensen, S.; Zhang, P.; Engelgau, 
M.M.; Ratner, R.E.; Herman, W.H. An Evaluation of Cost Sharing to Finance a Diet and Physical 
Activity Intervention to Prevent Diabetes. Diabetes Care 2006, 29, 1237–1241. 
41.  Hoerger,  T.J.;  Hicks,  K.A.;  Sorensen,  S.W.;  Herman,  W.H.;  Ratner,  R.E.;  Ackermann,  R.T.; 
Zhang, P.; Engelgau, M.M. Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight 
and Obese U.S. Adults. Diabetes Care 2007, 30, 2874–2879. 
42.  Icks, A.; Rathmann, W.; Haastert, B.; Gandjour, A.; Holle, R.; John, J.; Giani, G. Clinical and 
cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare 
setting: model based on the KORA Survey 2000. Diabet. Med. 2007, 24, 473–480. 
43.  Caro, J.J.; Getsios, D.; Caro, I.; Klittich, W.S.; Brien, J.A.O. Economic evaluation of therapeutic 
interventions to prevent Type 2 diabetes in Canada. Diabet. Med. 2004, 21, 1229–1236. 
44.  Eddy, D.M.; Schlessinger, L.; Kahn, R. Clinical Outcomes and Cost-Effectiveness of Strategies 
for Managing People at High Risk for Diabetes. Ann. Intern. Med. 2005, 143, 251–264. 
45.  Ramachandran, A.;  Snehalatha, C.; Yamuna,  A.; Mary, S.;  Ping, Z. Cost-effectiveness of the 
interventions in the primary prevention of diabetes among Asian Indians: within-trial results of 
the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007, 30, 2548–2552. 
46.  Galani,  C.;  Al,  M.;  Schneider,  H.;  Rutten,  F.F.  Uncertainty  in  decision-making:  value  of 
additional information in the cost-effectiveness of lifestyle intervention in overweight and obese 
people. Value Health 2008, 11, 424–434. 
47.  Galani, C.; Schneider, H.; Rutten, F. Modelling the lifetime costs and health effects of lifestyle 
intervention in the prevention and treatment of obesity in Switzerland. Int. J. Public Health 2007, 
52, 372–382. 
48.  Lindgren, P.; Lindstrom, J.; Tuomilehto, J.; Uusitupa, M.; Peltonen, M.; Jonsson, B.; de Faire, U.; 
Hellenius, M.-L.; The DPS Study Group. Lifestyle intervention to prevent diabetes in men and 
women with impaired glucose tolerance is cost-effective. Int. J. Technol. Assess. Health Care 
2007, 23, 177–183. 
49.  Brandeau,  M.L.  Modeling  Complex  Medical  Decision  Problems  with  the Archimedes Model. 
Ann. Intern. Med. 2005, 143, 303–304. 
50.  Engelgau, M.M. Trying To Predict the Future for People with Diabetes: A Tough but Important 
Task. Ann. Intern. Med. 2005, 143, 301–302. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3190 
51.  Eddy, D.M.; Schlessinger, L.; Kahn, R. Managing People at High Risk for Diabetes. Ann. Intern. 
Med. 2006, 144, 67–68. 
52.  Herman,  W.H.;  Hoerger,  T.J.;  Hicks,  K.;  Brandle,  M.;  Sorensen,  S.W.;  Zhang,  P.;  Engelgau, 
M.M.; Hamman, R.F.; Marrero, D.G.; Ackermann, R.T.; Ratner, R.E. Managing People at High 
Risk for Diabetes. Ann. Intern. Med. 2006, 144, 66–67. 
53.  Rappange, D.R.; van Baal, P.H.; van Exel, N.J.; Feenstra, T.L.; Rutten, F.F.; Brouwer, W.B. 
Unrelated medical costs in life-years gained: should they be included in economic evaluations of 
healthcare interventions? Pharmacoeconomics 2008, 26, 815–830. 
54.  Roux,  L.;  Pratt,  M.;  Tengs,  T.O.;  Yore,  M.M.;  Yanagawa,  T.L.;  Van  Den  Bos,  J.;  Rutt,  C.; 
Brownson, R.C.; Powell, K.E.; Heath, G.; Kohl Iii, H.W.; Teutsch, S.; Cawley, J.; Lee, I.M.; 
West,  L.;  Buchner,  D.M.  Cost  Effectiveness  of  Community-Based  Physical  Activity 
Interventions. Am. J. Prev. Med. 2008, 35, 578–588. 
55.  Dalziel, K.; Segal, L.; Elley, C.R. Cost utility analysis of physical activity counselling in general 
practice. Aust. N. Z. J. Public Health 2006, 30, 57–63. 
56.  Munro, J.; Brazier, J.; Davey, R.; Nicholl, J. Physical activity for the over-65s: could it be a cost-
effective exercise for the NHS? J. Public Health Med. 1997, 19, 397–402. 
57.  Stevens, W.; Hillsdon, M.; Thorogood, M.; McArdle, D. Cost-effectiveness of a primary care 
based physical activity intervention in 45–74 year old men and women: a randomised controlled 
trial. Br. J. Sports Med. 1998, 32, 236–241. 
58.  Larun, L.; Nordheim Lena, V.; Ekeland, E.; Hagen Kå re, B.; Heian, F. Exercise in prevention and 
treatment of anxiety and depression among children and young people. Cochrane Database Syst. 
Rev. 2006, 3, CD004691. 
59.  Ainsworth, B.E. How do I measure physical activity in my patients? Questionnaires and objective 
methods. Br. J. Sports Med. 2009, 43, 6–9. 
60.  Dalziel, K.; Segal, L. Time to give nutrition interventions a higher profile: cost-effectiveness of 10 
nutrition interventions. Health Promot. Int. 2007, 22, 271–283. 
61.  Tice, J.A.; Ross, E.; Coxson, P.G.; Rosenberg, I.; Weinstein, M.C.; Hunink, M.G.M.; Goldman, 
P.A.;  Williams,  L.;  Goldman,  L.  Cost-effectiveness  of  Vitamin  Therapy  to  Lower  Plasma 
Homocysteine Levels for the Prevention of Coronary Heart Disease: Effect of Grain Fortification 
and Beyond. JAMA 2001, 286, 936–943. 
62.  Cox, R.H.; White, A.H.; Gaylord, C.K. A video lesson series is effective in changing the dietary 
intakes and food-related behaviors of low-income homemakers. J. Am. Diet. Assoc. 2003, 103, 
1488–1493. 
63.  Bemelmans, W.; van Baal, P.; Wendel-Vos, W.; Schuit, J.; Feskens, E.; Ament, A.; Hoogenveen, 
R. The costs, effects and cost-effectiveness of counteracting overweight on a population level. A 
scientific base for policy targets for the Dutch national plan for action. Prev. Med. 2008, 46,  
127–132. 
64.  Booth, N.; Jula, A.; Aronen, P.; Kaila, M.; Klaukka, T.; Kukkonen-Harjula, K.; Reunanen, A.; 
Rissanen,  P.;  Sintonen,  H.;  Makela,  M.  Cost-effectiveness  analysis  of  guidelines  for 
antihypertensive care in Finland. BMC Health Serv. Res. 2007, 7, 172. 
65.  Colagiuri, S.; Walker, A.E. Using An Economic Model Of Diabetes To Evaluate Prevention And 
Care Strategies In Australia. Health Aff. 2008, 27, 256–268. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3191 
66.  Brown, H.S.; Perez, A.; Li, Y.-P.; Hoelscher, D.; Kelder, S.; Rivera, R. The cost-effectiveness of a 
school-based overweight program. Int. J. Behav. Nutr. Phys. Act. 2007, 4, 47. 
67.  Goldfield,  G.S.;  Epstein,  L.H.;  Kilanowski,  C.K.;  Paluch,  R.A.;  Kogut-Bossler,  B.  
Cost-effectiveness of group and mixed family-based treatment for childhood obesity. Int. J. Obes. 
Relat. Metab. Disord. 2001, 25, 1843–1849. 
68.  Wang, L.Y.; Yang, Q.; Lowry, R.; Wechsler, H. Economic Analysis of a School-Based Obesity 
Prevention Program. Obesity 2003, 11, 1313–1324. 
69.  Lindholm,  L.;  Rosen,  M.;  Weinehall,  L.;  Asplund,  K.  Cost  effectiveness  and  equity  of  a 
community based cardiovascular disease prevention programme in Norsjo, Sweden. J. Epidemiol. 
Community Health 1996, 50, 190–195. 
70.  Salkeld, G.; Phongsavan, P.; Oldenburg, B.; Johannesson, M.; Convery, P.; Graham-Clarke, P.; 
Walker, S.; Shaw, J. The cost-effectiveness of a cardiovascular risk reduction program in general 
practice. Health Policy 1997, 41, 105–119. 
71.  Finkelstein, E.A.; Khavjou, O.; Will, J.C. Cost-effectiveness of WISEWOMAN, a program aimed 
at reducing heart disease risk among low-income women. J. Womens Health (Larchmt) 2006, 15, 
379–389. 
72.  Finkelstein, E.A.; Troped, P.J.; Will, J.C.; Palombo, R. Cost-Effectiveness of a Cardiovascular 
Disease Risk Reduction Program Aimed at Financially Vulnerable Women: The Massachusetts 
WISEWOMAN Project. J. Womens Health Gend. Based Med. 2002, 11, 519–526. 
73.  Lindgren, P.; Fahlstadius, P.; Hellenius, M.L.; Jonsson, B.; de Faire, U. Cost-effectiveness of 
primary prevention of coronary heart disease through risk factor intervention in 60-year-old men 
from the county of Stockholm–a stochastic model of exercise and dietary advice.  Prev. Med. 
2003, 36, 403–409. 
74.  Dzator, J.A.; Hendrie, D.; Burke, V.; Gianguilio, N.; Gillam, H.F.; Beilin, L.J.; Houghton, S. A 
randomized trial of interactive group sessions achieved greater improvements in nutrition and 
physical activity at a tiny increase in cost. J. Clin. Epidemiol. 2004, 57, 610–619. 
75.  Jacobs-van der Bruggen, M.A.M.; Bos, G.; Bemelmans, W.J.; Hoogenveen, R.T.; Vijgen, S.M.; 
Baan,  C.A.  Lifestyle  Interventions  Are  Cost-Effective  in  People  With  Different  Levels  of 
Diabetes Risk: Results from a modeling study. Diabetes Care 2007, 30, 128–134. 
76.  Ara,  R.;  Brennan,  A.  The  cost-effectiveness  of  sibutramine  in  non-diabetic  obese  patients: 
evidence from four Western countries. Obes. Rev. 2007, 8, 363–371. 
77.  Brennan, A.; Ara, R.; Sterz, R.; Matiba, B.; Bergemann, R. Assessment of clinical and economic 
benefits of weight management with sibutramine in general practice in Germany. Eur. J. Health 
Econ. 2006, 7, 276–284. 
78.  Warren, E.; Brennan, A.; Akehurst, R. Cost-Effectiveness of Sibutramine in the Treatment of 
Obesity. Med. Decis. Making 2004, 24, 9–19. 
79.  Iannazzo, S.; Zaniolo, O.; Pradelli, L. Economic evaluation of treatment with orlistat in Italian 
obese patients. Curr. Med. Res. Opin. 2008, 24, 63–74. 
80.  van  Baal,  P.H.;  van  den  Berg,  M.;  Hoogenveen,  R.T.;  Vijgen,  S.M.;  Engelfriet,  P.M.  
Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health 
gains through prevention of obesity-related chronic diseases. Value Health 2008, 11, 1033–1040. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3192 
81.  Hampp, C.; Hartzema, A.G.; Kauf, T.L. Cost-utility analysis of rimonabant in the treatment of 
obesity. Value Health 2008, 11, 389–399. 
82.  Roux,  L.;  Kuntz,  K.M.;  Donaldson,  C.;  Goldie,  S.J.  Economic  Evaluation  of  Weight  Loss 
Interventions in Overweight and Obese Women. Obesity 2006, 14, 1093–1106. 
83.  Prosser, L.A.; Stinnett, A.A.; Goldman, P.A.; Williams, L.W.; Hunink, M.G.M.; Goldman, L.; 
Weinstein,  M.C.  Cost-Effectiveness  of  Cholesterol-Lowering  Therapies  according  to  Selected 
Patient Characteristics. Ann. Intern. Med. 2000, 132, 769–779. 
84.  Gillies, C.L.; Lambert, P.C.; Abrams, K.R.; Sutton, A.J.; Cooper, N.J.; Hsu, R.T.; Davies, M.J.; 
Khunti, K. Different strategies for screening and prevention of type 2 diabetes in adults: cost 
effectiveness analysis. BMJ 2008, 336, 1180–1185. 
85.  National  Institute  for  Health  and  Clinical  Excellence.  Obesity:  Guidance  on  the  Prevention, 
Identification, Assessment and Management of Overweight and Obesity in Adults and Children. 
Available  online:  http://www.nice.org.uk/nicemedia/pdf/CG43NICEGuideline.pdf  (accessed  on 
10 April 2010). 
86.  Neovius,  M.;  Narbro,  K.  Cost-effectiveness  of  pharmacological  anti-obesity  treatments:  a 
systematic review. Int. J. Obes. 2008, 32, 1752–1763. 
87.  Sevick,  M.A.;  Dunn,  A.L.;  Morrow,  M.S.;  Marcus,  B.H.;  Chen,  G.J.;  Blair,  S.N.  
Cost-effectiveness of lifestyle and structured exercise interventions in sedentary adults: Results of 
project ACTIVE. Am. J. Prev. Med. 2000, 19, 1–8. 
88.  Sims, J.; Huang, N.; Pietsch, J.; Naccarella, L. The Victorian Active Script Programme: promising 
signs for general practitioners, population health, and the promotion of physical activity. Br. J. 
Sports Med. 2004, 38, 19–25. 
89.  Joffres, M.R.; Campbell, N.R.; Manns, B.; Tu, K. Estimate of the benefits of a population-based 
reduction in dietary sodium additives on hypertension and its related health care costs in Canada. 
Can. J. Cardiol. 2007, 23, 437–443. 
90.  Panagiotakos,  D.;  Sitara,  M.;  Pitsavos,  C.;  Stefanadis,  C.  Estimating  the  10-Year  Risk  of 
Cardiovascular  Disease  and  Its  Economic  Consequences,  by  the  Level  of  Adherence  to  the 
Mediterranean Diet: The ATTICA Study. J. Med. Food 2007, 10, 239–243. 
91.  McConnon,  A.;  Kirk,  S.F.;  Cockroft,  J.E.;  Harvey,  E.L.;  Greenwood,  D.C.;  Thomas,  J.D.; 
Ransley,  J.K.;  Bojke,  L.  The  Internet  for  weight  control  in  an  obese  sample:  results  of  a 
randomised controlled trial. BMC Health Serv. Res. 2007, 7, 206. 
92.  Philips,  Z.;  Bojke,  L.;  Sculpher,  M.;  Claxton,  K.;  Golder,  S.  Good  practice  guidelines  for 
decision-analytic  modelling  in  health  technology  assessment:  a  review  and  consolidation  of 
quality assessment. Pharmacoeconomics 2006, 24, 355–371. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3193 
93.  Weinstein, M.C.; O‘Brien, B.; Hornberger, J.; Jackson, J.; Johannesson, M.; McCabe, C.; Luce, 
B.R.  Principles  of  Good  Practice  for  Decision  Analytic  Modeling  in  Health-Care  Evaluation: 
Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 
2003, 6, 9–17. 
94.  Weinstein, M.C. Recent developments in decision-analytic modelling for economic evaluation. 
Pharmacoeconomics 2006, 24, 1043–1053. 
95.  McCabe, C.; Claxton, K.; Culyer, A.J. The NICE Cost-Effectiveness Threshold: What it is and 
what that means. Pharmacoeconomics 2008, 26, 733–744. 
96.  National  Institute  for  Health  and  Clinical  Excellence.  Guide  to  the  Methods  of  Technology 
Appraisal. Available online: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf (accessed 
on 10 April 2010). 
97.  Weinstein, M.C.P. How Much Are Americans Willing to Pay for a Quality-Adjusted Life Year? 
Med. Care 2008, 46, 343–345. 
98.  Moodie, M.; Haby, M.; Wake, M.; Gold, L.; Carter, R. Cost-effectiveness of a family-based GP-
mediated intervention targeting overweight and moderately obese children. Econ. Hum. Biol. 
2008, 6, 363–376. 
99.  Murray,  C.J.L.;  Evans,  D.B.;  Acharya,  A.;  Baltussen,  R.M.P.M.  Development  of  WHO 
guidelines on generalized cost-effectiveness analysis. Health Econ. 2000, 9, 235–251. 
100.  Claxton, K.; Briggs, A.; Buxton, M.J.; Culyer, A.J.; McCabe, C.; Walker, S.; Sculpher, M.J. 
Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008, 336, 251–254. 
101.  Raftery, J. Should NICE's threshold range for cost per QALY be raised? No. BMJ 2009, 338, 
b185. 
102.  Braithwaite, R.S.; Meltzer, D.O.; King, J.T.J.; Leslie, D.; Roberts, M.S. What Does the Value of 
Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? Med. 
Care 2008, 46, 349–356. 
103.  Towse, A. Should NICE‘s threshold range for cost per QALY be raised? Yes. BMJ 2009, 338, 
b181. 
104.  Bridges,  J.F.P.;  Onukwugha,  E.;  Mullins,  C.D.  Healthcare  Rationing  by  Proxy:  
Cost-Effectiveness  Analysis  and  the  Misuse  of  the  $50  000  Threshold  in  the  US. 
Pharmacoeconomics 2010, 28, 175–184. 
105.  Bell, C.M.; Urbach, D.R.; Ray, J.G.; Bayoumi, A.; Rosen, A.B.; Greenberg, D.; Neumann, P.J. 
Bias in published cost effectiveness studies: systematic review. BMJ 2006, 332, 699–703. 
106.  Decision Analytic Modelling in the Economic Evaluation of Health Technologies: A Consensus 
Statement. Pharmacoeconomics 2000, 17, 443–444. 
107.  Sculpher, M.; Fenwick, E.; Claxton, K. Assessing quality in decision analytic cost-effectiveness 
models.  A  suggested  framework  and  example  of  application.  Pharmacoeconomics  2000,  17, 
461–477. 
108.  Soto,  J.  Health  economic  evaluations  using  decision  analytic  modeling.  Principles  and 
practices—utilization of a checklist to their development and appraisal. Int. J. Technol. Assess. 
Health Care 2002, 18, 94–111. 
109.  Kim, L.G.; Thompson, S.G. Uncertainty and validation of health economic decision models. 
Health Econ. 2010, 19, 43–55. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3194 
110.  McCabe, C.; Dixon, S. Testing the Validity of Cost-Effectiveness Models. Pharmacoeconomics 
2000, 17, 501–513. 
111.  Cantor, S.B. Is it time for reporting guidelines for calibration methods? Pharmacoeconomics 
2009, 27, 529–531. 
112.  Eddy, D.M. Accuracy versus Transparency in Pharmacoeconomic Modelling: Finding the Right 
Balance. Pharmacoeconomics 2006, 24, 837–844. 
113.  Uusitupa,  M.;  Peltonen,  M.;  Lindströ m,  J.;  Aunola,  S.;  Ilanne-Parikka,  P.;  
Keinä nen-Kiukaanniemi,  S.;  Valle,  T.T.;  Eriksson,  J.G.;  Tuomilehto,  J.;  Finnish  Diabetes 
Prevention  Study  Group.  Ten-Year  Mortality  and  Cardiovascular  Morbidity  in  the  Finnish 
Diabetes Prevention Study—Secondary Analysis of the Randomized Trial. PLoS ONE 2009, 4, 
e5656. 
114.  Siebert,  U.  When  should  decision-analytic  modeling  be  used  in  the  economic  evaluation  of 
health care? Eur. J. Health Econ. 2003, 4, 143–150. 
115.  Ronckers, E.T.; Groot, W.; Ament, A.J.H.A. Systematic Review of Economic Evaluations of 
Smoking  Cessation:  Standardizing  the  Cost-Effectiveness.  Med.  Decis.  Making  2005,  25,  
437–448. 
116.  Wang, D.; Connock, M.; Barton, P.; Fry-Smith, A.; Aveyard, P.; Moore, D. ‗Cut down to quit‘ 
with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness 
and economic analysis. Health Technol. Assess. 2008, 12, 1–135. 
117.  Chiou, C.F.; Hay, J.W.; Wallace, J.F.; Bloom, B.S.; Neumann, P.J.; Sullivan, S.D.; Yu, H.T.; 
Keeler, E.B.; Henning, J.M.; Ofman, J.J. Development and validation of a grading system for the 
quality of cost-effectiveness studies. Med. Care 2003, 41, 32–44. 
118.  Drummond,  M.F.;  Jefferson,  T.O.  Guidelines  for  authors  and  peer  reviewers  of  economic 
submissions  to  the  BMJ.  The  BMJ  Economic  Evaluation  Working  Party.  BMJ  1996,  313,  
275–283. 
119.  Evers, S.; Goossens, M.; de Vet, H.; van Tulder, M.; Ament, A. Criteria list for assessment of 
methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int. J. 
Technol. Assess. Health Care 2005, 21, 240–245. 
120.  Gerkens, S.; Crott, R.; Cleemput, I.; Thissen, J.-P.; Closon, M.-C.; Horsmans, Y.; Beguin, C. 
Comparison  of  three  instruments  assessing  the  quality  of  economic  evaluations:  A  practical 
exercise on economic evaluations of the surgical treatment of obesity. Int. J. Technol. Assess. 
Health Care 2008, 24, 318–325. 
121.  Anderson, R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2010, 
19, 350–364. 
122.  Sculpher, M.J.; Pang, F.S.; Manca, A.; Drummond, M.F.; Golder, S.; Urdahl, H.; Davies, L.M.; 
Eastwood, A. Generalisability in economic evaluation studies in healthcare: a review and case 
studies. Health Technol. Assess. 2004, 8, 1–192. 
123.  Welte, R.; Feenstra, T.; Jager, H.; Leidl, R. A Decision Chart for Assessing and Improving the 
Transferability of Economic Evaluation Results Between Countries. Pharmacoeconomics 2004, 
22, 857–876. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3195 
124.  National  Institute  for  Health  and  Clinical  Excellence.  Modelling  the  Cost  Effectiveness  of 
Physical  Activity  Interventions.  Available  online:  http://www.nice.org.uk/nicemedia/pdf/ 
FourmethodsEconomicModellingReport.pdf (accessed on 10 April 2010). 
125.  Johansson,  P.  Economic  Evaluation  of  Public  Health  Programmes—Constraints  and 
Opportunities;  Doctoral  thesis.  Karolinska  Institutet:  Stockholm,  Sweden,  2009.  Available 
online: http://diss.kib.ki.se/2009/978-91-7409-317-9/thesis.pdf (accessed on 10 April 2010). 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 